Affymax (AFFY) 10-Q 5 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 31, 2013
Entity Information [Line Items]	'	'
Entity Registrant Name	'AFFYMAX INC	'
Entity Central Index Key	'0001158223	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	37,490,137
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$6,852	$68,265
Short-term investments	0	9,717
Receivable from Takeda	0	18,365
Deferred tax assets	0	363
Prepaid expenses	591	2,731
Other current assets	0	3,069
Total current assets	7,443	102,510
Property and equipment, net	0	2,981
Restricted cash	0	1,135
Long-term investments	0	2,323
Deferred tax assets, net of current	7,240	6,876
Other assets	862	2,392
Total assets	15,545	118,217
Current liabilities	'	'
Accounts payable	157	6,591
Accrued liabilities	828	52,522
Accrued clinical trial expenses	0	2,844
Deposit from Takeda	0	559
Advance from Takeda	8,189	27,715
Notes payable, current	0	8,844
Total current liabilities	9,174	99,075
Long-term income tax liability	7,240	10,062
Other long-term liabilities	0	799
Total liabilities	16,414	109,936
Commitments and contingencies (Note 9)	'	'
Stockholders' equity	'	'
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding	0	0
Common stock: $0.001 par value, 100,000,000 shares authorized, 37,490,137 and 37,369,717 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively	37	37
Additional paid-in capital	555,802	551,959
Accumulated deficit	-556,706	-543,713
Accumulated other comprehensive loss	-2	-2
Total stockholders’ equity (deficit)	-869	8,281
Total liabilities and stockholders’ equity	$15,545	$118,217

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	37,490,137	37,369,717
Common stock, shares outstanding	37,490,137	37,369,717

CONDENSED_STATEMENTS_OF_COMPRE

CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Collaboration revenue	$0	$13,603	$1,364	$79,562
License and royalty revenue	0	4	5	9
Total revenue	0	13,607	1,369	79,571
Research and development	-166	11,416	11,805	40,486
Selling, general and administrative	1,886	26,181	26,740	62,936
Collaboration cost reimbursement	'	'	-43,451	0
Impairment (gain on disposal) of prepaid expenses, fixed assets and intangible assets	-166	0	4,414	0
Restructuring charge	138	0	15,478	0
Total operating expenses	1,692	37,597	14,986	103,422
Loss from operations	-1,692	-23,990	-13,617	-23,851
Interest income	0	23	21	56
Interest expense	0	-668	-1,565	-1,316
Other income (expense), net	0	-3	10	-29
Loss before provision for income taxes	-1,692	-24,638	-15,151	-25,140
(Benefit) provision for income taxes	0	0	-2,158	1
Net loss	-1,692	-24,638	-12,993	-25,141
Earnings Per Share, Basic and Diluted	($0.05)	($0.68)	($0.35)	($0.70)
Weighted Average Number of Shares Outstanding, Basic and Diluted	37,490	36,350	37,483	36,067
Total comprehensive loss	($1,692)	($24,641)	($12,993)	($25,158)

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities	'	'
Net loss	($12,993)	($25,141)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Collaboration cost reimbursement	-41,777	0
Impairment of prepaid expenses, fixed assets and intangible assets	4,414	0
Noncash restructuring charge	331	0
Depreciation and amortization	574	1,450
Amortization of premium on investments	2	75
Stock-based compensation expense	3,572	7,987
Loss (gain) on disposal of property and equipment	-704	30
Noncash interest expense	812	513
Changes in operating assets and liabilities:	'	'
Receivable from Takeda	18,365	-96
Inventory	0	-2,040
Prepaid expenses and other current assets	3,661	-5,225
Other assets	220	236
Accounts payable	-6,435	2,825
Accrued liabilities	-29,763	4,015
Accrued clinical trial expenses	-2,844	-865
Increase (Decrease) in Deferred Revenue	'	7,212
Deposit from Takeda	-559	-1,438
Long-term income tax liability	-2,159	102
Other long-term liabilities	-799	-444
Net cash used in operating activities	-66,082	-10,804
Cash flows from investing activities	'	'
Purchases of property and equipment	0	-1,215
Proceeds from maturities of investments	13,173	44,065
Proceeds from sale of property and equipment	1,225	25
Net cash provided by investing activities	14,398	30,699
Cash flows from financing activities	'	'
Proceeds from issuance of common stock upon exercise of stock options	271	4,495
Proceeds from issuance of common stock under employee stock purchase plan	0	440
Proceeds from note payable	0	10,000
Repayment of note payable	-10,000	0
Net cash (used in) provided by financing activities	-9,729	14,935
Net (decrease) increase in cash and cash equivalents	-61,413	34,830
Cash and cash equivalents at beginning of the period	68,265	54,339
Cash and cash equivalents at end of the period	6,852	89,169
Supplemental schedule of non-cash financing activities:	'	'
Warrants issued in connection with notes payable	0	1,394
Proceeds from Collection of Advance to Affiliate	'	2,676
Payments to Acquire Intangible Assets	'	-2,500
Payments to Acquire Investments	'	$9,676

The_Company

The Company	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
The Company	'
	The Company
	Affymax, Inc., a Delaware corporation, was incorporated in July 2001. We are a biopharmaceutical company in the process of restructuring operations. In March 2012, the U.S. Food and Drug Administration, or FDA, approved our first and only product, OMONTYS® (peginesatide) Injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.  OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.  We co-commercialized OMONTYS with our collaboration partner, Takeda Pharmaceutical Company Limited, or Takeda during 2012 until February 2013, when we and Takeda announced a nationwide voluntary recall of OMONTYS as a result of safety concerns. Effective April 1, 2013, we entered into an amendment of our collaboration with Takeda pursuant to which Takeda assumed full responsibility for OMONTYS, including responsibility for the ongoing recall and investigation with the FDA, and we granted them an exclusive worldwide license to OMONTYS in consideration for potential milestones and royalties.
	We have experienced significant operating losses since inception. The recall of OMONTYS has severely harmed our business, financial condition, and prospects as a going concern and even with the transition of responsibilities effectuated by the Takeda amendment and the reductions in force, these planned cost reductions may not be sufficient to continue as a going concern. We continue to take steps to reduce our outstanding obligations to third parties, and are dependent on those efforts to continue operations even in the near term, which may not be successful. The recall has also limited our access to funds. We may be unable to continue our operations or to succeed in the existing and potential future litigation, particularly with the reductions in force and in view of our limited resources and funds. We may explore various strategic alternatives, including a sale of the Company or our assets or a corporate merger. We are considering all possible alternatives, including further restructuring activities, wind-down of operations or bankruptcy proceedings. As of September 30, 2013, we had an accumulated deficit of $556.7 million.
	Product Recall
	On February 23, 2013, we and Takeda announced a nationwide voluntary recall of OMONTYS as a result of post marketing reports regarding safety concerns, including anaphylaxis, which can be life-threatening or fatal. As a result of the voluntary recall of OMONTYS, all marketing activities were suspended and we have also suspended or terminated manufacturing activities.
	Restructuring and Impairment
	In March 2013, we commenced a restructuring plan to reduce operating costs, which included a reduction in force of approximately 305 employees. As of September 30, 2013 there are four employees remaining.  We incurred approximately $15.5 million in restructuring charges for the nine months ended September 30, 2013, all of which are related to expenditures for one-time employee termination benefits (see Note 11 of the Notes to Condensed Financial Statements).  As a result of this restructuring and the recall, we also recorded impairment changes with respect to our property and equipment and intangible assets related to our license from Janssen Biotech, Inc. (a subsidiary of Johnson & Johnson) and certain of its affiliated companies, collectively referred to as Janssen, in the first quarter of 2013 (see Note 4 of the Notes to Condensed Financial Statements).
	Effective April 1, 2013, we and Takeda, collectively the Parties, entered into the Fourth Amendment, or the Amendment, to the February 13, 2006 and June 27, 2006 Collaboration and License Agreements to amend and restate the ongoing respective roles and responsibilities and related commitments and financial terms between the Parties, including the termination of the Collaboration and License Agreement dated as of February 13, 2006, under which we granted Takeda a certain right and license for the development and commercialization in Japan of OMONTYS, as amended by the First Amendment, dated April 1, 2007, the Second Amendment, dated January 1, 2008 and the Third Amendment, dated November 7, 2011, as well as the related manufacturing supply, safety, quality and co-promotion agreements between the Parties. The Amendment revised the economics from a profit-sharing arrangement to a milestone and royalty-based compensation structure to us effective as of April 1, 2013. This Amendment is part of our ongoing restructuring efforts resulting from the voluntary recall announced on February 23, 2013 related to OMONTYS, the suspension of U.S. marketing and promotional activities, and the ongoing investigation with the FDA. The arrangement with Takeda including the Amendment is referred to as the Arrangement.
	The Amendment effectuated a transfer of product and regulatory responsibilities, including the OMONTYS New Drug Application, or NDA, and all manufacturing, and development responsibilities from us to Takeda. Takeda received a worldwide, exclusive royalty-bearing license under our and joint Takeda-Affymax patents to develop, manufacture and commercialize OMONTYS.
	As a result of the Amendment, Takeda assumed full responsibility for OMONTYS, including the ongoing recall and investigation of OMONTYS as well as any subsequent decisions as to whether the product may be subject to reintroduction if Takeda is able to complete the investigation and address the safety concerns to the satisfaction of the FDA. If Takeda decides to reintroduce OMONTYS, which is highly uncertain, we are eligible to receive royalties and (i) potential commercial milestone payments totaling up to $180.0 million which consists of the following: (a) $10.0 million is payable upon the first commercial sale after reintroduction of OMONTYS in the U.S.; (b) $10.0 million and another $10.0 million relates to U.S. sales-based milestones, and (c) $150.0 million relates to sales-based milestones in amounts as previously disclosed outside of the U.S. but now including Japan as a result of the Amendment and (ii) a potential development milestone payment of $5.0 million payable either upon regulatory approval in the E.U. or Japan. The royalties are tiered in the range of 13% to 17% with respect to net sales in the U.S. and in the range of 13% to 24% depending on the level of net sales by Takeda worldwide outside of the U.S. As of September 30, 2013, we have retained a liability for an advance from Takeda on our condensed balance sheet of approximately $8.2 million, which Takeda may offset a percentage of future royalty and milestone payments due to us, if any against the advance recorded (see Note 3 of the Notes to Condensed Financial Statements).
	In April 2013, as part of our efforts to restructure our operations in order to reduce costs, in addition to our reduction in force, we engaged an experienced restructuring firm, The Brenner Group, Inc. With the engagement of the restructuring firm, we terminated the employment of our remaining executive officers, including our former Chief Executive Officer and Chief Financial Officer.
	Going Concern
	Because we have not made an irrevocable decision to liquidate, the accompanying condensed financial statements have been prepared under the assumption of a going concern basis that contemplates the realization of assets and liabilities in the ordinary course of business. Operating losses have been incurred each year since inception, resulting in an accumulated deficit of $556.7 million as of September 30, 2013. Nearly all of our revenues to date have come from our collaboration with Takeda. As a result of the February 23, 2013 nationwide voluntary recall of OMONTYS and the suspension of all marketing activities, there is significant uncertainty as to whether we will have sufficient existing cash to fund our operations for the next 12 months. Our liabilities exceed our assets. Given our limited resources, there is no assurance that we will be able to reduce our operating expenses enough to meet our existing and future obligations and conduct ongoing operations. If we do not have sufficient funds to continue operations, we could be required to liquidate our assets, seek bankruptcy protection or other alternatives. Any failure to dispel any continuing doubts about our ability to continue as a going concern could adversely affect our ability to enter into collaborative relationships with business partners. These matters raise substantial doubt about our ability to continue as a going concern. Our financial statements do not include any adjustments that may result from the outcome of this uncertainty.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Summary of Significant Accounting Policies
	Basis of Presentation
	Our accompanying condensed financial statements have been prepared following the requirements of the Securities and Exchange Commission, or SEC, for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles, or GAAP, have been condensed or omitted. The condensed financial statements are unaudited and reflect all adjustments, consisting of only normal recurring adjustments, which, in the opinion of management, are necessary to fairly state the financial position at, and the results of operations and cash flows for, the interim periods presented.  The financial information included herein should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2012, which includes our audited financial statements and the notes thereto.
	Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in the condensed financial statements and accompanying notes may not be indicative of the results for the full year or any future period.
	Concentration of Risk
	Financial instruments that potentially subject us to a concentration of credit risk consist of cash, cash equivalents and investments. We deposit excess cash in accounts with major financial institutions in the U.S. Deposits in these banks may exceed the amount of insurance provided on such deposits. We have not experienced any realized losses on our deposits of cash and cash equivalents.
	Our future revenue is based on only one source of product-related revenue, OMONTYS. If Takeda is not successful in identifying the cause and is unable or unwilling to reintroduce OMONTYS, we have no prospects for other sources of revenue.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	Revenue Recognition
	Collaboration Revenue
	We recognize revenue for contracts entered into prior to 2011 in accordance with the SEC Staff Bulletin No. 101, Revenue Recognition in Financial Statements, as amended by Staff Accounting Bulletin or SAB, No. 104, Revision of Topic 13 and Accounting Standards Codification or ASC, 605-25, Multiple Element Arrangements.  When evaluating multiple element arrangements, we consider whether the components of the arrangement represent separate units of accounting as defined in the authoritative guidance for revenue arrangements with multiple deliverables. Application of this guidance requires subjective determinations and requires management to make judgments about the fair value of the individual elements and whether such elements are separable from the other aspects of the contractual relationship. We continue to follow the guidance of ASC 605-25 to determine whether the components of the Arrangement represent separate units of accounting.  To determine if a delivered item can be treated as a separate unit of accounting, we evaluate (1) if the delivered item(s) has value to Takeda on a standalone basis; (2) there is objective and reliable evidence of fair value of the undelivered item(s) and (3) if a general right of return exists for the delivered item (e.g. contingencies), delivery or performance of the undelivered item(s) is considered probable and is substantially within the control of the Company.  We recognize revenue for contracts entered into or materially modified after January 1, 2011, in accordance with Accounting Standards Update, or ASU, No. 2009-13, Multiple Deliverable Revenue Arrangements. This update amends the guidance on accounting for arrangements with multiple deliverables to require that each deliverable be evaluated to determine whether it qualifies as a separate unit of accounting.  This determination is generally based on whether the deliverable has stand-alone value to the customer.  This update also establishes a selling price hierarchy for determining how to allocate arrangement consideration to identified units of accounting.  The selling price used for each unit of accounting will be based on vendor-specific objective evidence, or VSOE, if available, third-party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third-party evidence is available.  We may be required to exercise considerable judgment in determining whether a deliverable is a separate unit of accounting and the estimated selling price of identified units of accounting for new or modified agreements.
	We account for our Arrangement with Takeda under ASC 605-25 and through the date of the recall, had been operating in the commercialization period as defined in the Arrangement.  Before the recall, we were performing commercialization services such as promotions and marketing as well as development work related to OMONTYS post approval.  In return for these services, we received a 50/50 share of operating profit from the sale and distribution of OMONTYS (as described below), certain milestone payments and contingent payments due under the Arrangement. We also received reimbursement of costs for commercial and development costs as described in the Arrangement. Prior to approval of OMONTYS, our primary source of revenue consisted of milestone payments and Takeda’s reimbursement of commercialization and development costs.
	In addition to the profit sharing and reimbursement of the costs described above, the Arrangement provides us the potential to earn substantive at risk milestone payments upon achievement of contractual criteria (see Note 3 of Notes to Financial Statements). However, timing and amounts of these milestones are highly uncertain due to the recall.
	During the commercialization period, our obligations included ongoing regulatory work to obtain and maintain FDA approval and commercialization efforts related to our product launch and promotion and marketing of OMONTYS.
	For each source of collaboration revenue, we apply the following revenue recognition model:
	•	Expense reimbursement revenue. Revenues related to reimbursements by Takeda of third-party development expenses (70/30 split per the Arrangement) and commercialization expenses (shared 50/50 according to the Arrangement) are recognized as revenue in the period the related costs are incurred.  Revenues related to reimbursement of costs of full-time equivalents, or FTEs, engaged in development related activities such as post-marketing studies, are recognized as revenue in the period the related costs are incurred. Such reimbursement is based on contractually negotiated reimbursement rates for each FTE as specified in the Arrangement.  Subsequent to the launch of OMONTYS and recognition of product revenue by Takeda, reimbursement of commercialization expenses and development costs (both FTE and out of pocket costs) associated with post-marketing development activities, is incorporated into the profit equalization revenue as required under the Arrangement in order to effect the 50/50 profit split, as described below.  As part of the Amendment with Takeda, both Parties agreed that they will no longer share expenses related to third-party development (70/30 split) and commercialization (50/50 split) as of April 1, 2013. Except for certain transition services that we performed in April 2013 for full reimbursement of $0.5 million, any expenses incurred by either us or Takeda after April 1, 2013 shall be the responsibility of the respective party and neither us or Takeda has the obligation to share expenses with each other.
	•	Profit equalization revenue/loss. Subsequent to the launch of OMONTYS and prior to the Amendment, as to the recognition of product revenue by Takeda, Takeda allocates the quarterly profit equalization revenue/loss to us in order to effect the 50/50 profit/loss split from the sale of OMONTYS, as called for by the Arrangement.  Profit equalization revenue/loss is calculated as the amount required so that the profit or loss realized by both us and Takeda on the product equates to 50% of the total product profit or loss.  Total product profit or loss on OMONTYS is calculated on a quarterly basis as gross product sales recorded by Takeda less the following deductions also recorded by Takeda: rebates and discounts, cost of goods, and other gross-to-net adjustments incurred by Takeda; royalty expenses incurred by us, commercialization expenses (FTE related and out of pocket costs) incurred by both Takeda and us, and certain development costs associated with post-marketing development activities (FTE related and out of pocket costs) incurred by both Takeda and us.  Profit equalization revenue is recognized as revenue in the period product revenue is recognized by Takeda.  As a result of the voluntary recall of OMONTYS in February 2013, all marketing activities were suspended. As part of the Amendment with Takeda, the profit equalization revenue for the three months ended March 31, 2013 will be the final profit equalization payment under the Arrangement. Upon signing the Amendment with Takeda, the economics of the collaboration changed from a profit sharing arrangement to a milestone and royalty-based compensation structure to us, effective April 1, 2013.
	•	Milestone revenue. We account for milestones under ASU No. 2010-17, Milestone Method of Revenue Recognition. Under the milestone method, contingent consideration received from the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved, which we believe is more consistent with the substance of our performance under the collaboration. A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity’s performance or on the occurrence of a specific outcome resulting from the entity’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, and (iii) that would result in additional payments being due to the entity. A milestone is substantive if the consideration earned from the achievement of the milestone is consistent with our performance required to achieve the milestone or the increase in value to the collaboration resulting from our performance, relates solely to our past performance, and is reasonable relative to all of the other deliverables and payments within the collaboration. Although we are eligible to receive future milestones from Takeda, timing and amounts of future milestone payments, if any are highly uncertain due to the recall.
	Below is a summary of the components of our collaboration revenue for the three and nine months ended September 30, 2013, and 2012 (in thousands):
		Three months ended September 30, 2013						Nine months ended September 30, 2013
		2013			2012			2013		2012
	Profit equalization payment	$	—		$	10,377		$	5	$	13,048
	Milestone payments	—			2,250			—		60,250
	Revenue previously deferred related to API	—			441			—		441
	Net expense reimbursement after CAPM	—			535			1,364		5,823
	Total collaboration revenue	$	—		$	13,603		$	1,369	$	79,562
	License and Royalty Revenue
	Royalties are recognized as earned in accordance with contract terms, when third party results are reported and collectability is reasonably assured.  Royalties received under agreements that were acquired by us in the 2001 spin out from GlaxoSmithKline or Glaxo are recorded net of the 50% that we are required to remit to Glaxo.
	If Takeda decides to reintroduce OMONTYS, which is highly uncertain, we are eligible to receive potential milestones and royalties. The royalties are tiered in the range of 13% to 17% with respect to net sales in the U.S. and in the range of 13% to 24% depending on the level of net sales by Takeda worldwide outside of the U.S.
	Inventory
	We value our inventories at the lower of cost or net realizable value which is contractually determined in our collaboration with Takeda to be our cost plus a markup.  We determine the cost of inventory using the specific identification method.  We record active pharmaceutical ingredient, or API, as inventory when the title transfers to us from the contract manufacturing organization, or CMO, until the point of acceptance by Takeda. We initiate orders for API with our CMOs based on forecasts from Takeda. To date, all orders have generally commenced once there was a contractual commitment for the API from Takeda.
	We analyze our inventory levels quarterly and write down inventory that has become obsolete or has a cost basis in excess of its expected net realizable value, as well as any inventory quantities in excess of expected requirements.  Any expired inventory is disposed of and the related costs are recognized as expense. The voluntary recall of OMONTYS in February 2013 impacted the recoverability of our inventories based on assumptions about expected demand and net realizable value. In the December 31, 2012 balance sheet, given the significant uncertainty of demand following the recall, we had written down our API inventory and prepayments made to our CMOs to the net realizable value of zero. We also established an accrual for estimated losses on firm inventory purchase commitments by applying the same lower of cost or market approach that is used to value inventory. As of March 31, 2013 this accrued commitment was $32.9 million. However, in the second quarter, we were able to settle these obligations for $11.0 million resulting in a favorable adjustment to our operating results of $21.9 million in the quarter ended June 30, 2013. As of September 30, 2013, there was no remaining accrued balance.
	We expense costs relating to the production of API as research and development or R&D expense in the period incurred until we receive FDA approval for a new product or product configuration and began to capitalize the subsequent inventory costs relating to that product or product configuration. Prior to approval of OMONTYS for commercial sale in March 2012 by the FDA, we had expensed all costs associated with the production of API as R&D expense. Subsequent to receiving FDA approval of OMONTYS, we commenced capitalization of third party costs which are incurred to manufacture the API used in the production of OMONTYS.
	Property and Equipment
	Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are calculated using the straight-line method over the estimated useful lives of the assets, generally three to five years. Assets under capital lease and leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the related lease. Maintenance and repairs are charged to operations as incurred. All equipment was determined to be held for sale in May 2013 and accordingly no further depreciation was recorded after that determination. Equipment categorized as held for sale on the balance sheet at May 31, 2013 had a net book value of $0.5 million. All equipment other than computers retained for data storage was sold as of June 30, 2013 and the carrying value of equipment was reduced to zero upon completion of the sale.
	Valuation of Long-Lived Assets, Prepaids and Other Assets
	We assess the impairment of long-lived assets when events or changes in circumstances indicate that the carrying value of the assets or the asset grouping may not be recoverable. Factors that we consider in deciding when to perform an impairment review include significant negative industry or economic trends, and significant changes or planned changes in our use of the assets. We measure the recoverability of assets that will continue to be used in our operations by comparing the carrying value of the asset grouping to our estimate of the related total future undiscounted net cash flows. If an asset grouping's carrying value is not recoverable through the related undiscounted cash flows, the asset grouping is considered to be impaired. The impairment is measured by comparing the difference between the asset grouping's carrying value and its fair value. Fair value is the price that would be received from selling an asset in an orderly transaction between market participants at the measurement date. Long-lived assets such as intangible assets and property, plant and equipment are considered non-financial assets, and are recorded at fair value only when an impairment charge is recognized. The recall of OMONTYS was considered to be an impairment indicator for certain assets. We evaluated the recoverability of our assets and determined that certain assets were impaired. We recorded impairment charges for the nine months ended September 30, 2013 of $4.4 million. These charges are reflected in the statement of comprehensive income (loss) under the caption "Impairment (gain on disposal) of prepaid expenses, fixed assets, and intangible assets."
	Net Loss Per Common Share
	Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for potential common shares.
	Diluted net loss per share is computed similarly to basic net loss per share, except that the denominator is increased to include all dilutive potential common shares using the treasury stock method.  For purposes of this calculation, options to purchase common stock, common stock issuable pursuant to the 2006 Employee Stock Purchase Plan, restricted stock units, or RSUs, and warrants are considered to be potential common shares and are only included in the calculation of diluted (loss) income per share when their effect is dilutive.
	The following shares were excluded in the computation of diluted net loss per common share for the periods presented because including them would have an anti-dilutive effect (in thousands):
		Three months ended September 30, 2013					Nine months ended September 30, 2013
		2013		2012			2013		2012
	Options to purchase common stock	1,893		5,311			1,893		5,311
	Common stock issuable pursuant to the 2006 Employee Stock Purchase Plan	—		125			—		125
	Restricted stock units	—		317			—		317
	Warrant to purchase common stock	424		504			424		504
	Stock-Based Compensation
	We account for equity instruments issued to employees and directors under the authoritative guidance for share-based payments.
	The equity instruments we most typically grant are stock options and RSUs. Stock options are valued using the Black-Scholes valuation model while the fair value of RSUs is equivalent to the market value of the equivalent number of shares of common stock on the date of grant. The measurement of stock-based compensation is subject to periodic adjustments as the underlying equity instruments vest or do not vest as a result of employee terminations prior to vest.
	We have issued stock options to non-employees. We account for equity instruments issued to non-employees in accordance with the authoritative guidance for equity-based payments to non-employees, using a fair value approach.
	During the quarter ended June 30, 2013, we terminated the Employee Stock Purchase Plan and the Restricted Stock Award Plan.

Development_and_Commercializat

Development and Commercialization Agreements with Takeda	9 Months Ended
	Sep. 30, 2013
Development and Commercialization Agreements [Abstract]	'
Development and Commercialization Agreements with Takeda	'
	Development and Commercialization Agreements with Takeda
	We entered into two separate collaboration agreements with Takeda in February 2006 and June 2006 related to the co-development and co-commercialization of OMONTYS, which have been combined for accounting purposes due to their proximity of negotiation. We previously amended these arrangements in November 2011 concurrent with the settlement and license agreement, or Settlement and License Agreement, with Janssen (see further discussion below and Note 4 of Notes to Condensed Financial Statements).
	On February 23, 2013, we and Takeda announced a nationwide voluntary recall of OMONTYS as a result of postmarketing reports regarding safety concerns, including anaphylaxis. As a result of the voluntary recall of OMONTYS, all marketing activities were suspended. Effective April 1, 2013, we and Takeda entered into the Amendment to the February 2006 and June 2006 agreements to amend and restate the ongoing respective roles and responsibilities and related commitments and financial terms between the Parties, including the termination of the Collaboration and License Agreement dated as of February 13, 2006, under which we had granted Takeda a certain right and license for the development and commercialization in Japan of OMONTYS, as amended by the First Amendment, dated April 1, 2007, the Second Amendment, dated January 1, 2008 and the Third Amendment, dated November 7, 2011, as well as the related manufacturing supply, safety, quality and co-promotion agreements between the parties. The Amendment revised the economics from a profit-sharing arrangement to a milestone and royalty-based compensation structure to us effective as of April 1, 2013. The Amendment is part of our ongoing restructuring efforts resulting from the voluntary recall announced on February 23, 2013 related to OMONTYS, the suspension of U.S. marketing and promotional activities, and the ongoing investigation with the FDA.
	The Amendment effectuated a transfer of regulatory responsibilities, including the OMONTYS NDA, and all manufacturing, and development responsibilities from us to Takeda. Takeda received a worldwide, exclusive royalty-bearing license under our and joint Takeda-Affymax patents to develop, manufacture and commercialize OMONTYS.
	As a result of the Amendment, Takeda assumed full responsibility for OMONTYS, including the ongoing recall and investigation of OMONTYS as well as any subsequent decisions as to whether the product may be subject to reintroduction if Takeda is able to complete the investigation and address the safety concerns to the satisfaction of the FDA. With the transfer of responsibilities and the NDA, Takeda is responsible for continuing the investigation but there can be no assurance as to when and if a solution will be identified.
	Collaboration revenue reported on our statement of comprehensive income (loss) consists of the nonrefundable upfront license fees, reimbursement for the sale of API net of costs incurred, net reimbursement of certain development and commercial expenses, revenues from product profit sharing, and milestone payments. We recognized $0.0 million and $13.6 million of collaboration revenue during the three months ended September 30, 2013 and 2012, respectively. The amount receivable from Takeda as of September 30, 2013 and December 31, 2012 was $0.0 million and $18.4 million, respectively.
	Development and Commercialization of OMONTYS in the U.S. Prior to the April 2013 Amendment
	Prior to the Amendment, Takeda bore responsibility for 70% of all third-party expenses related to U.S. development and 50% of all third party expenses related to U.S. commercialization. Certain employee-related expenses supporting the commercialization of OMONTYS in the U.S. were also shared equally.  In addition, costs of certain employees in clinical, regulatory and other development functions supporting any post-marketing development activities such as additional clinical trials required by the FDA as a condition of the approval of OMONTYS in March 2012 or other activities separately agreed to by the parties in the U.S. were shared equally. As part of the Amendment between us and Takeda, both Parties agreed that they will no longer share expenses related to third-party development (70/30 split) and commercialization (50/50 split) as of April 1, 2013. Any expenses incurred by either us or Takeda after April 1, 2013 shall be the responsibility of the respective party and neither us or Takeda has the right to share expenses with each other.
	In February 2012, as contemplated under the Arrangement, we and Takeda entered into a Co-Promotion Agreement to further specify and formalize terms and conditions relating to the joint U.S. commercialization activities for OMONTYS including a corporate governance structure and division of roles and responsibilities between us and Takeda, including deployment of resources. Prior to the Amendment, we were responsible for deployment of the sales force and the medical affairs field force but shared marketing, account management and payor reimbursement related activities with Takeda. Takeda was responsible for manufacturing and distribution of the finished drug product to the customer and recorded product sales of OMONTYS. Specifically, Takeda had sole responsibility for handling all returns, order processing, invoicing and collection of receivables with regard to sales of OMONTYS. Takeda also had the rights and responsibility for establishing and modifying terms and conditions with respect to the sale of OMONTYS in the U.S., including pricing discounts available to third party payers, price adjustments and other allowable discounts and allowances. In addition, as we and Takeda split profits 50/50 in the U.S., the Co-Promotion Agreement provided further detail relating to the treatment of FTE expenses used to calculate eligible commercial expenses incurred by us and Takeda thereunder. Consistent with the terms of the Arrangement, Takeda retained final decision making authority with respect to terms related to pricing and contracting and responsibility for distribution activities.
	Prior to the Amendment, while Takeda was responsible for the sale of OMONTYS and accordingly Takeda recorded product revenue, we and Takeda shared equally in the net profits and losses of those sales of OMONTYS in the U.S. In determining the OMONTYS net profit or loss, OMONTYS product revenue was reduced by rebates and discounts, cost of goods, and other gross-to-net adjustments incurred by Takeda; royalty expense incurred by us, commercialization expenses (FTE related and out of pocket costs) incurred by both Takeda and us, and certain development costs associated with post-marketing development activities (FTE related and out of pocket costs) incurred by both Takeda and us. We reviewed the revenue, related deductions and expenses provided by Takeda and prepared an invoice to Takeda for our portion of the OMONTYS net profit after factoring in applicable costs incurred by us and Takeda at the end of each quarter. The profit equalization amount was recognized as revenue in the period the product sales occurred and product revenue was recognized by Takeda.
	As a result of the voluntary recall of OMONTYS in February 2013, all marketing activities were suspended. As part of the Amendment with Takeda, the profit equalization revenue for the six months ended June 30, 2013 was the final profit equalization payment under the Arrangement. Upon signing the Amendment with Takeda, the economics of the collaboration changed from a profit sharing arrangement to a milestone and royalty-based compensation structure to us, effective April 1, 2013.
	Development and Commercialization of OMONTYS outside of the U.S.
	In February 2006, we granted an exclusive license to Takeda for development and commercialization of OMONTYS in Japan. In December 2011, Takeda announced that it had decided not to commercialize OMONTYS in Japan. We and Takeda have explored other options for the commercialization rights for OMONTYS in the Japanese market, including potentially licensing it to a third party. If Takeda or its licensee is successful in clinical development and regulatory milestones, we are eligible to receive contingent payments from Takeda which aggregate up to $33.0 million relating to the Japan renal program and $5.0 million for a third indication that neither we or Takeda is pursuing. Per the terms of the Amendment, the Japan agreement was terminated.
	In June 2006, Takeda subsequently received an exclusive license to develop and commercialize the product outside of the U.S. Takeda bears all costs for product clinical development in support of regulatory approval for all territories outside the U.S. and will pay us a variable royalty based on annual net sales of the product outside the U.S. In February 2012, Takeda announced the acceptance for assessment from the European Medicines Agency or EMA of a Marketing Authorization Application or MAA for OMONTYS for the treatment of symptomatic anemia associated with chronic kidney disease in adult patients on dialysis.  The application is currently under review by that agency.
	Launch Allowance
	As noted above, Takeda bore responsibility for 50% of all third party expenses related to the commercialization of OMONTYS in the U.S. Takeda also provided a launch allowance to help fund the initial costs associated with preparing to launch under which it committed to fund the first $20.0 million of U.S. commercial expenses incurred in total by us and Takeda. Amounts received under the launch allowance are non-refundable; under the Amendment, however, Takeda is entitled to deduct up to 8% from any future payments made to us under the royalty or milestone provisions until they have recouped an amount equal to $11.0 million ($10.0 million plus a $1.0 million fixed amount that represents interest). As of September 30, 2013, our liability balance under the launch allowance is $8.2 million.
	Milestones
	During 2012, we earned the following milestone payments from Takeda: a $50.0 million milestone upon FDA approval of OMONTYS in the dialysis indication, a $5.0 million milestone upon acceptance for review of the MAA, filing for OMONTYS by the EMA, and a $3.0 million and $2.3 million milestone related to an amendment to the Arrangement or the November 2011 Amendment, described below.
	As a result of the Amendment, Takeda assumed full responsibility for OMONTYS, including the ongoing recall and investigation of OMONTYS as well as any subsequent decisions as to whether the product may be subject to reintroduction if Takeda is able to complete the investigation and address the safety concerns to the satisfaction of the FDA. We provided transition support to Takeda through April 30, 2013. After April 30, 2013 we have no performance obligations under our agreement with Takeda. If Takeda decides to reintroduce OMONTYS, all of which is highly uncertain, we are eligible to receive royalties and (i) potential contingent payments in the form of commercial milestone payments totaling up to $180.0 million, which consist of the following: (a) $10.0 million is payable upon the first commercial sale after reintroduction of OMONTYS in the U.S.: (b) $10.0 million and another $10.0 million relates to U.S. sales-based milestones, and (c) $150.0 million relates to sales-based milestones outside of the U.S. as disclosed below but now including Japan as a result of the Amendment and (ii) a potential development milestone payment of $5.0 million payable either upon regulatory approval in the E.U. or Japan. The royalties are tiered in the range of 13% to 17% with respect to net sales in the U.S. and in the range of 13% to 24% depending on the level of net sales by Takeda worldwide outside of the U.S. The $150.0 million of sales-based milestones consists of milestones of $10.0 million, $20.0 million, $30.0 million, $40.0 million and $50.0 million for worldwide net sales reached and recorded by Takeda during a fiscal year of the arrangement of $0.5 billion, $1.0 billion, $1.5 billion, $2.0 billion and $3.0 billion, respectively. Although we are eligible to receive future milestones from Takeda, timing and amounts of future milestone payments, if any, are highly uncertain due to the recall.
	API Supply Agreement
	In November 2011, as contemplated under the Arrangement, we and Takeda executed a Commercial API Supply Agreement. Under the terms of the API Supply Agreement, we were responsible for the manufacture and supply of all quantities of API to be used in the development and commercialization of OMONTYS worldwide. Takeda reimbursed us for our cost of API plus 20%. Takeda was responsible for the fill and finish steps in the manufacture of OMONTYS worldwide under the Arrangement. As of December 31, 2012 we had a balance of $19.8 million recorded as an Advance from Takeda which was related to deferred revenue on API shipped to Takeda. As a result of the recall and the impairment charges recorded on the OMONTYS inventory during 2012, the remaining balance of deferred revenue was reversed as of June 30, 2013.
	Impairment of Inventory and Firm Purchase Commitments
	Prior to the voluntary recall, we initiated orders for API with our CMOs based on forecasts from Takeda, which were based on expected demand for OMONTYS. Orders generally had commenced once there was a contractual commitment for the API from Takeda. In the quarter ended June 30, 2013 we settled these obligations for less than the contractual amounts. We made a total of $11.0 million in payments to settle our obligations to three CMOs and recorded a favorable adjustment to our operating results of $21.9 million.
	In addition to the binding CMO purchase commitments, we also had $10.4 million in inventory and prepayments made to our CMOs on our balance sheet as of December 31, 2012. As a result of the inability to sell OMONTYS and the uncertainty of future revenues, we have written down our API inventory and prepayments for API being produced by our CMOs to a net realizable value of zero and recorded a $10.4 million impairment charge related to this writedown during the year ended December 31, 2012. Of the total $45.0 million charge for impairment of inventory and loss on CMO purchase commitments recorded in 2012, we recorded a benefit of $23.1 million in the first quarter of 2013, primarily related to the collaboration cost reimbursement under the Takeda Q1 profit equalization payment. As a result of the fourth Amendment, Takeda assumed full responsibility for OMONTYS. This includes the ongoing investigation of OMONTYS as well as any subsequent decisions as to whether the product may be subject to reintroduction. Reintroduction would be possible only if Takeda is able to complete the investigation and address the safety concerns to the satisfaction of the FDA.
	Cost of Recall
	As a result of the fourth Amendment, Takeda assumed full responsibility for OMONTYS. This includes the ongoing investigation of OMONTYS as well as any subsequent decisions as to whether the product may be subject to reintroduction. Reintroduction would be possible only if Takeda is able to complete the investigation and address the safety concerns to the satisfaction of the FDA.
	The total costs of recalling the product were primarily composed of costs to a third-party to gather, store, and return the product to Takeda, of which $1.1 million was incurred in the first quarter of 2013. Our portion of the expense was $0.6 million which we were charged as a part of the Q1 profit equalization payment in the first quarter of 2013.
	Takeda capitalizes inventory costs associated with the production of OMONTYS and enters into purchase commitments for goods associated with this manufacturing. The write down or write off of such inventory and any charges for purchase commitments by Takeda was subject to the profit equalization revenue or loss calculation of the Arrangement. Takeda included inventory write down charges of $31.8 million for the cost of inventory on hand at Takeda as of March 31, 2013 in the Q1 profit equalization payment. Our portion of this write down was $15.9 million and was previously reserved for as of December 31, 2012 as a part of our Advance from Takeda liability. With respect to purchase commitments, Takeda requested reimbursement for a portion of the costs associated with Takeda's firm purchase commitment of $9.3 million with Baxter for pre-filled syringes. Our exposure was limited to the portion of the Baxter agreement that relates to the U.S. We had no liability related to the E.U. or Japan because in those countries we receive only a royalty on product sales and the collaboration profit split did not apply to operations in those countries. The amount of our exposure was $0.7 million which was included in the Q1 profit equalization payment in the first quarter of 2013.
	In the first quarter of 2013, Takeda recorded an impairment charge for certain long lived assets associated with OMONTYS.  Under the profit/loss equalization we were responsible for half of these charges.  Our exposure related to this impairment was $6.2 million.  This amount was charged to us as a part of the Q1 profit equalization payment in the first quarter of 2013.
	November 2011 Amendment
	In November 2011, concurrent with the execution of the Settlement and License Agreement with Janssen, we and Takeda entered into an amendment to the Arrangement. Under the terms of this amendment, Takeda agreed to pay up to $6.5 million in additional milestones to us in consideration of the upfront and milestone payments we are required to make to Janssen under the Settlement and License Agreement. Approximately $5.3 million of these milestones were earned based on regulatory and commercial events in the U.S. and the remaining $1.3 million tied to regulatory events in the E.U, which was eliminated as part of the Amendment.  We recognized $3.0 million of these milestones in the first quarter of 2012 as it was earned as a result of FDA approval in March 2012.

Contractual_Arrangements

Contractual Arrangements	9 Months Ended
	Sep. 30, 2013
Settlement and License Agreement [Abstract]	'
Contractual Arrangements	'
	Contractual Arrangements
	Our License, Manufacturing and Supply Agreement with Nektar
	In April 2004, we entered into a License, Manufacturing and Supply Agreement with Nektar Therapeutics AL Corporation, or Nektar, under which we obtained from Nektar a worldwide, non-exclusive license, with limited rights to grant sublicenses, under certain intellectual property covering pegylation technology to manufacture, develop and commercialize OMONTYS. The license we obtained consists of a license under intellectual property owned by Nektar and a sublicense under intellectual property owned by Enzon Pharmaceuticals, Inc., or Enzon, licensed to Nektar pursuant to a cross-license agreement between Nektar, Inhale Therapeutic Systems, Inc. and Enzon.
	In consideration of the license grant, we agreed to pay royalties on the sales of OMONTYS, which began with the launch of the product in the U.S. in 2012; sales of the product were suspended on February 26, 2013. We also agreed to pay base milestones plus possible additional milestones in connection with our partnering activities relating to OMONTYS or merger and acquisition activities. As of September 30, 2013, no further milestone obligations remain.
	Contract Manufacturing Organization (CMO) Settlements
	We initiated orders for API with our CMOs based on forecasts from Takeda, which were based on expected demand for OMONTYS. Orders generally commenced once there was a contractual commitment for the API from Takeda. As of December 31, 2012, we had future purchase commitments amounting to $34.6 million. These future commitments were comprised of $5.8 million for firm purchase commitments of PEG, and the remaining $28.8 million of manufacturing obligations relate to API, and were based on firm demand forecasts from Takeda. We paid $1.7 million in payments to our CMOs in our first quarter 2013 which reduced the accrual balance to $32.9 million.
	We finalized settlement agreements with the CMOs in the second quarter of 2013 and made a total of $11.0 million in payments resulting in a favorable adjustment to our second quarter 2013 operating results of $21.9 million.
	Settlement and License Agreement with Janssen
	In November 2011, we entered into the Settlement and License Agreement with Janssen under which we obtained a non-exclusive license to the intellectual property in dispute, a covenant not to sue and a release of all claims associated with the arbitration and dispute. The Settlement and License Agreement also provides for the dismissal of all pending proceedings. The Settlement and License Agreement required us to make two fixed payments to Janssen, $6.0 million, which was paid in December 2011, and $2.0 million, which was paid in June 2012.  Upon execution of the Settlement and License Agreement in the fourth quarter of 2011, we recorded $8.0 million of R&D expense relating to the fixed payments.  The Settlement and License Agreement also required us to make a $2.5 million milestone payment to Janssen upon FDA regulatory approval of OMONTYS, and requires us to make a $2.5 million milestone payment to Janssen upon regulatory approval of OMONTYS in the first major European country. Upon FDA approval in March 2012, we capitalized $2.5 million related to the first milestone payment during the first quarter of 2012 as another asset. The resulting asset was to be be amortized over the expected life of the related patent family, the last-expiring patent of which expires in June 2016. This $2.5 million milestone payment was paid to Janssen in April 2012. During the nine months ended September 30, 2013, as a result of the recall, we recorded a $1.9 million impairment charge related to this asset, bringing the asset value to zero.
	In addition, Janssen will be entitled to low, single-digit royalties on sales of OMONTYS in Europe, Japan and certain other countries outside of the United States until mid-2016. This royalty payment is not reimbursable under our Arrangement with Takeda.

Balance_Sheet_Components

Balance Sheet Components	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Balance Sheet Components	'
	Balance Sheet Components
	Property and Equipment, Net
	Property and equipment consist of the following (in thousands):
		September 30,		December 31,
		2013		2012
	Leasehold improvements	$	—	$	2,501
	Equipment	—		9,794
	Software	—		3,064
	Construction in progress	—		9
		—		15,368
	Less: Accumulated depreciation and amortization	—		(12,387		)
		$	—	$	2,981
	Depreciation and amortization expense for the nine months ended September 30, 2013 and 2012 was $0.6 million and $1.5 million, respectively. In addition to the expense noted above, we also incurred $1.9 million in impairment charges for the nine months ended September 30, 2013. In May of 2013 management committed to a plan to sell all of the company's property and equipment. The assets were classified as held for sale and depreciation expense was recorded through May 15, 2013. The assets were sold in June of 2013 for $1.1 million. The book value of the assets sold was $0.5 million and a gain of $0.6 million was recorded in the three months ended June 30, 2013. In the three months ended September 30, 2013 additional proceeds of $0.1 million were received resulting in a total gain on the sale of assets of $0.7 million for the nine months ended September 30, 2013.
	Accrued Liabilities
	Accrued liabilities consist of the following (in thousands):
		September 30,		December 31,
		2013		2012
	Accrued potential losses related to firm purchase commitments (1)	$	—	$	34,599
	Restructuring accrual (2)	587		—
	Compensation-related expenses	—		12,837
	SG&A related costs	241		3,633
	R&D related costs	—		830
	Other	—		623
		$	828	$	52,522
	(1) See Note 3 of Notes to Condensed Financial Statements.
	(2) See Note 11 of Notes to Condensed Financial Statements.

Investments

Investments	9 Months Ended
	Sep. 30, 2013
Available-for-sale Securities [Abstract]	'
Investments	'
	Investments
	We held no investments as of September 30, 2013. A summary of our investments outstanding as of December 31, 2012 is as follows (in thousands):
		As of December 31, 2012
		Cost		Gross		Gross			Fair Value
				Unrealized		Unrealized
				Gains		Losses
	Short-term investments:
	Certificates of deposit	$	1,300	$	—	$	—		$	1,300
	Corporate debt securities	8,416		1		—			8,417
	Total short-term investments	$	9,716	$	1	$	—		$	9,717
	Long-term investments:
	Corporate debt securities	$	2,326	$	—	$	(3	)	$	2,323
	Total long-term investments	$	2,326	$	—	$	(3	)	$	2,323
	.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	Fair Value Measurements
	We measure certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and available for sale securities.  The fair value of these assets was determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:
	•	Level 1 — observable inputs such as quoted prices in active markets.
	•	Level 2 — inputs other than quoted prices in active markets that are observable either directly or indirectly through corroboration with observable market data.
	•	Level 3 — unobservable inputs in which there is little or no market data, which would require us to develop our own assumptions.
	The types of investments that are generally classified within Level 1 of the fair value hierarchy include money market securities. The valuation technique we used to measure fair value of our Level 1 money market securities is a market approach, using prices and other relevant information generated by market transactions involving identical securities.  The types of investments that are generally classified within Level 2 of the fair value hierarchy include corporate securities, certificates of deposits and U.S. government securities.  The valuation technique we used to measure fair value of our Level 2 investments is a market approach, under which we review trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical investments was not available, we used market pricing and other observable market inputs for similar investments obtained from various third party data providers. These inputs represent quoted prices for similar investments in active markets or these inputs have been derived from observable market data.
	Financial instruments that are not recorded at fair value are measured at fair value on a quarterly basis for disclosure purposes. The fair value of the notes payable are based on the present value of expected future cash flows, assumptions about current interest rates and the creditworthiness of Affymax. Market risk associated with our fixed rate debt relates to the potential reduction in fair value.  The carrying amounts of our notes payable approximate fair value.
	The carrying amounts of certain financial instruments, such as cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximates fair value due to their relatively short maturities, and low market interest rates if applicable.
	We held no assets or liabilities as of September 30, 2013 which were remeasured to fair value on a recurring basis.
	The following table presents as of December 31, 2012 our investments measured at fair value on a recurring basis classified by the fair value measurements and disclosures valuation hierarchy (in thousands):
		As of December 31, 2012
				Fair Value Measurements Using
		Total		Level 1		Level 2		Level 3
	Money market funds	$	45,999	$	45,999	$	—	$	—
	Short-term investments:
	Certificates of deposit	$	1,300	$	—	$	1,300	$	—
	Corporate debt securities	8,417		—		8,417		—
	Total short-term investments	$	9,717	$	—	$	9,717	$	—
	Long term investments:
	Corporate debt securities	$	2,323	$	—	$	2,323	$	—
	Total long-term investments	$	2,323	$	—	$	2,323	$	—
	In conjunction with the product recall and related restructuring activities, management evaluated our property and equipment and committed to a plan to sell all non-essential equipment. Equipment and leasehold improvements were categorized as held for sale in May 2013 and sold in June 2013. No equipment or other fixed assets remain on the balance sheet at September 30, 2013.

Loan_and_Security_Agreement

Loan and Security Agreement	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Loan and Security Agreement	'
	Loan and Security Agreement and Repayment
	In March 2012, we entered into a loan and security agreement, or the Loan Agreement, with Oxford Finance LLC and Silicon Valley Bank, or, collectively, the Lenders, under which we borrowed $10.0 million.
	On April 3, 2013, we entered into a Letter Agreement, under which (i) we paid all amounts due and owing so as to discharge our obligations thereunder which totaled $9.8 million including remaining principal, interest, final payment and prepayment fees, (ii) we waived any rights to seek additional credit extensions or unfunded commitments under the Loan Agreement, and (iii) the security interest granted to Lenders relating to substantially all of our assets, other than our intellectual property, was terminated. As of September 30, 2013, we had no remaining notes payable outstanding.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	Legal Proceedings
	On February 27, 2013, a securities class action complaint was filed in the United States District Court for the Northern District of California, naming as defendants Affymax, Inc. or the Company, certain of its officers, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A., Inc. and Takeda Global Research & Development Center, Inc.  A second complaint naming the same defendants was filed on March 6, 2013.  On May 2, 2013, the securities class action complaint that was filed on February 27, 2013 was voluntarily dismissed by the plaintiff.  On May 21, 2013, the Court appointed a lead plaintiff in the remaining securities class action complaint.  On July 22, 2013, an amended class action complaint was filed on behalf of purported stockholders of the Company, naming as defendants the Company and certain of its former officers.  The amended complaint alleges violations of Section 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, in connection with allegedly false and misleading statements made by the defendants regarding OMONTYS and the Company's business practices, financial projections and other disclosures between August 8, 2012 and February 22, 2013, or the Class Period.  The plaintiff seeks to represent a class comprised of purchasers of the Company's common stock during the Class Period and seeks damages, costs and expenses and such other relief as determined by the Court.  On September 20, 2013, the Company and the individual defendants filed a motion to dismiss the consolidated amended complaint. The hearing on the motion to dismiss is set for January 14, 2014.
	On March 19, 2013, and March 29, 2013, respectively, two derivative lawsuits were filed purportedly on behalf of the Company in California Superior Court for the County of Santa Clara naming certain of our current and former officers and directors as defendants (the “State Court Derivative Action”). The lawsuits allege that the certain of the Company's officers and directors breached their fiduciary duties related to the clinical trials for OMONTYS and for representations regarding the Company's business health which was tied to the success of OMONTYS.  The lawsuits also assert claims for unjust enrichment and corporate waste. On May 31, 2013, the Court consolidated the two actions and appointed lead plaintiff.  On June 11, 2013, lead plaintiff designated the complaint filed on March 29, 2013 as the operative complaint. On August 6, 2013, the Court stayed the derivative action pending the outcome of the motion to dismiss in the securities class action.
	On August 19, 2013, another derivative lawsuit was filed purportedly on behalf of the Company in the United States District Court for the Northern District of California naming certain of our current and former officers and directors as defendants (the “Federal Derivative Action”). The lawsuit’s allegations are substantially similar to the allegations in the State Court Derivative Action. On October 9, 2013, the parties stipulated to stay the Federal Derivative Action pending the outcome of the motion to dismiss in the securities class action.
	We believe that we have meritorious defenses and intend to defend these lawsuits vigorously. However, these lawsuits are subject to inherent uncertainties, the actual cost may be significant, and we may not prevail. We believe we are entitled to coverage under our relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient.
	Additionally, in light of the recall, a product liability claim could potentially arise, although no claim has been filed to date.
	We assess litigation to determine if an unfavorable outcome would lead to a probable loss or reasonable possible loss, which could be estimated.  We accrue for losses that are both probable and reasonably estimable. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.  In the cases where we believe that a reasonable possible loss exists, we disclose the facts and circumstances of the litigation, including an estimable range, if possible.  Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonable possible loss. Accordingly, no loss accrual has been established for the above.  While it is not possible to accurately predict or determine the eventual outcome of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our financial condition, results of operations or cash flows.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation	'
	Stock-Based Compensation
	During the nine months ended September 30, 2013, we terminated substantially all of our employees. Upon termination, the difference between the expected forfeiture rate and the actual forfeiture rate was adjusted in the recognition of the stock-based compensation, and resulted in an offset to expense for some groups of employees. Stock-based compensation was recorded in the statements of operations as follows (in thousands):
		Three Months Ended September 30,						Nine Months Ended
								September 30,
		2013			2012			2013			2012
	Research and development	$	—		$	1,086		$	825		$	3,240
	Selling, general and administrative	499			1,719			2,747			4,747
	Total	$	499		$	2,805		$	3,572		$	7,987
	We granted the following stock options, RSUs and performance RSUs, or PRSUs to employees as follows:
		Nine Months Ended September 30,
		2013
		Number of		Weighted-
		Shares		Average Grant
				Date Fair Value
				Per Share
	Stock options	888,778		$	15.79
	Restricted stock units	331,195		$	19.42
	Performance restricted stock units	62,000		$	19.43
	Stock Option and Restricted Stock Unit Activity
	The following tables summarize information about stock option and RSU activity for the nine months ended September 30, 2013:
		Number of		Weighted-			Weighted-		Aggregate
		Shares		Average Exercise Price			Average		Intrinsic Value
				(Per Share)(1)			Remaining		(in thousands)(2)
							Contractual
							Term
							(in years)
	Stock Options:
	Balances at December 31, 2012	4,857,536		$	13.49
	Granted	888,778		18.83
	Exercised	(30,918	)	8.77
	Forfeited	(2,889,025	)	13.35
	Cancelled	(933,724	)	13.08
	Balances at September 30, 2013	1,892,647		$	16.49		3.71		$	—
	Options exercisable at September 30, 2013	1,549,755		$	17.5		2.76		$	—
		Number of		Weighted-			Weighted-		Aggregate
		Shares		Average Grant Date Fair Value			Average		Intrinsic Value
				(Per Share)(1)			Remaining		(in thousands)(2)
							Contractual
							Term
							(in years)
	Restricted Stock Units:
	Balances at December 31, 2012	296,723		$	7.54
	Granted (time-based)	393,195		19.42
	Vested	(89,502	)	7.58
	Forfeited	(600,416	)	15.19
	Balances at September 30, 2013	—		$	—		0		$	—
	_______________________________________________________________________________
	-1	The weighted average price per share is determined using exercise price per share for stock options and fair value per share on grant date for restricted stock units.
	-2	The aggregate intrinsic value is calculated as:
	•	For options: the difference between the exercise price of the option and the fair value of our common stock for in-the-money options at September 30, 2013.
	•	For restricted stock units: the difference between the grant date fair value of the unit and the fair value of our common stock for in-the-money units at September 30, 2013.

Restructuring_Charge

Restructuring Charge	9 Months Ended
	Sep. 30, 2013
Restructuring and Related Activities [Abstract]	'
Restructuring Charge	'
	Restructuring Charge
	2013 Restructuring
	On February 23, 2013, we and Takeda announced a nationwide voluntary recall of OMONTYS as a result of post marketing reports regarding safety concerns, including anaphylaxis, which can be life-threatening or fatal. As a result of the voluntary recall of OMONTYS, all marketing activities were suspended and we have also suspended or terminated manufacturing activities.
	In March 2013, we began implementing plans to restructure our operations in order to reduce operating costs and focus on the OMONTYS safety and other related FDA issues associated with the recall of the product. As of June 30, 2013, in addition to transitioning many of the ongoing activities to our collaborator, Takeda, we completed a reduction in force of almost all our personnel, including all of our commercial and medical affairs field forces as well as other employees throughout the organization.  We have recorded $15.5 million in restructuring charges related to the workforce reduction and facilities during the first nine months of 2013.
	The following table summarizes the accrual balance and utilization by type for the restructuring (in thousands):
		Facilities			Employee			Total
		Related			Related
	Balance at December 31, 2012	$	—		$	—		$	—
	Restructuring charges accrued	2,500			13,841			16,341
	Adjustments	—			214			214
	Cash payments	(2,500		)	(13,451		)	(15,951		)
	Accretion	(17		)	—			(17		)
	Balance at September 30, 2013	$	(17	)	$	604		$	587
	In April 2013, as part of our efforts to restructure our operations in order to reduce costs, in addition to our reduction in force, we engaged an experienced restructuring firm, The Brenner Group. With the engagement of the restructuring firm, we terminated the employment of our former executive officers, including our Chief Executive Officer and Chief Financial Officer.

Provision_for_income_Taxes

Provision for income Taxes	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure	'
	12. Provision for Income Taxes
	We are subject to federal and state income taxes. While we did generate net income during the second quarter of 2013 due to significant non-recurring adjustments to impairment charges, we anticipate being in a net operating loss position for 2013 and therefore have not recorded any federal or state taxes, other than the minimum statutory California tax, related to the current period for the three and nine months ended September 30, 2013. We did however record a $2.2 million tax benefit for a lapse in statute of limitations on a previously reserved uncertain state and federal tax positions. We did not record any tax liability for the nine months ended September 30, 2012 other than the minimum statutory California tax due to the anticipated tax loss position for the year ended December 31, 2012.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	Our accompanying condensed financial statements have been prepared following the requirements of the Securities and Exchange Commission, or SEC, for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles, or GAAP, have been condensed or omitted. The condensed financial statements are unaudited and reflect all adjustments, consisting of only normal recurring adjustments, which, in the opinion of management, are necessary to fairly state the financial position at, and the results of operations and cash flows for, the interim periods presented.  The financial information included herein should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2012, which includes our audited financial statements and the notes thereto.
	Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in the condensed financial statements and accompanying notes may not be indicative of the results for the full year or any future period.
Concentration of Risk	'
	Concentration of Risk
	Financial instruments that potentially subject us to a concentration of credit risk consist of cash, cash equivalents and investments. We deposit excess cash in accounts with major financial institutions in the U.S. Deposits in these banks may exceed the amount of insurance provided on such deposits. We have not experienced any realized losses on our deposits of cash and cash equivalents.
	Our future revenue is based on only one source of product-related revenue, OMONTYS. If Takeda is not successful in identifying the cause and is unable or unwilling to reintroduce OMONTYS, we have no prospects for other sources of revenue.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Revenue Recognition	'
	Revenue Recognition
	Collaboration Revenue
	We recognize revenue for contracts entered into prior to 2011 in accordance with the SEC Staff Bulletin No. 101, Revenue Recognition in Financial Statements, as amended by Staff Accounting Bulletin or SAB, No. 104, Revision of Topic 13 and Accounting Standards Codification or ASC, 605-25, Multiple Element Arrangements.  When evaluating multiple element arrangements, we consider whether the components of the arrangement represent separate units of accounting as defined in the authoritative guidance for revenue arrangements with multiple deliverables. Application of this guidance requires subjective determinations and requires management to make judgments about the fair value of the individual elements and whether such elements are separable from the other aspects of the contractual relationship. We continue to follow the guidance of ASC 605-25 to determine whether the components of the Arrangement represent separate units of accounting.  To determine if a delivered item can be treated as a separate unit of accounting, we evaluate (1) if the delivered item(s) has value to Takeda on a standalone basis; (2) there is objective and reliable evidence of fair value of the undelivered item(s) and (3) if a general right of return exists for the delivered item (e.g. contingencies), delivery or performance of the undelivered item(s) is considered probable and is substantially within the control of the Company.  We recognize revenue for contracts entered into or materially modified after January 1, 2011, in accordance with Accounting Standards Update, or ASU, No. 2009-13, Multiple Deliverable Revenue Arrangements. This update amends the guidance on accounting for arrangements with multiple deliverables to require that each deliverable be evaluated to determine whether it qualifies as a separate unit of accounting.  This determination is generally based on whether the deliverable has stand-alone value to the customer.  This update also establishes a selling price hierarchy for determining how to allocate arrangement consideration to identified units of accounting.  The selling price used for each unit of accounting will be based on vendor-specific objective evidence, or VSOE, if available, third-party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third-party evidence is available.  We may be required to exercise considerable judgment in determining whether a deliverable is a separate unit of accounting and the estimated selling price of identified units of accounting for new or modified agreements.
	We account for our Arrangement with Takeda under ASC 605-25 and through the date of the recall, had been operating in the commercialization period as defined in the Arrangement.  Before the recall, we were performing commercialization services such as promotions and marketing as well as development work related to OMONTYS post approval.  In return for these services, we received a 50/50 share of operating profit from the sale and distribution of OMONTYS (as described below), certain milestone payments and contingent payments due under the Arrangement. We also received reimbursement of costs for commercial and development costs as described in the Arrangement. Prior to approval of OMONTYS, our primary source of revenue consisted of milestone payments and Takeda’s reimbursement of commercialization and development costs.
	In addition to the profit sharing and reimbursement of the costs described above, the Arrangement provides us the potential to earn substantive at risk milestone payments upon achievement of contractual criteria (see Note 3 of Notes to Financial Statements). However, timing and amounts of these milestones are highly uncertain due to the recall.
	During the commercialization period, our obligations included ongoing regulatory work to obtain and maintain FDA approval and commercialization efforts related to our product launch and promotion and marketing of OMONTYS.
	For each source of collaboration revenue, we apply the following revenue recognition model:
	•	Expense reimbursement revenue. Revenues related to reimbursements by Takeda of third-party development expenses (70/30 split per the Arrangement) and commercialization expenses (shared 50/50 according to the Arrangement) are recognized as revenue in the period the related costs are incurred.  Revenues related to reimbursement of costs of full-time equivalents, or FTEs, engaged in development related activities such as post-marketing studies, are recognized as revenue in the period the related costs are incurred. Such reimbursement is based on contractually negotiated reimbursement rates for each FTE as specified in the Arrangement.  Subsequent to the launch of OMONTYS and recognition of product revenue by Takeda, reimbursement of commercialization expenses and development costs (both FTE and out of pocket costs) associated with post-marketing development activities, is incorporated into the profit equalization revenue as required under the Arrangement in order to effect the 50/50 profit split, as described below.  As part of the Amendment with Takeda, both Parties agreed that they will no longer share expenses related to third-party development (70/30 split) and commercialization (50/50 split) as of April 1, 2013. Except for certain transition services that we performed in April 2013 for full reimbursement of $0.5 million, any expenses incurred by either us or Takeda after April 1, 2013 shall be the responsibility of the respective party and neither us or Takeda has the obligation to share expenses with each other.
	•	Profit equalization revenue/loss. Subsequent to the launch of OMONTYS and prior to the Amendment, as to the recognition of product revenue by Takeda, Takeda allocates the quarterly profit equalization revenue/loss to us in order to effect the 50/50 profit/loss split from the sale of OMONTYS, as called for by the Arrangement.  Profit equalization revenue/loss is calculated as the amount required so that the profit or loss realized by both us and Takeda on the product equates to 50% of the total product profit or loss.  Total product profit or loss on OMONTYS is calculated on a quarterly basis as gross product sales recorded by Takeda less the following deductions also recorded by Takeda: rebates and discounts, cost of goods, and other gross-to-net adjustments incurred by Takeda; royalty expenses incurred by us, commercialization expenses (FTE related and out of pocket costs) incurred by both Takeda and us, and certain development costs associated with post-marketing development activities (FTE related and out of pocket costs) incurred by both Takeda and us.  Profit equalization revenue is recognized as revenue in the period product revenue is recognized by Takeda.  As a result of the voluntary recall of OMONTYS in February 2013, all marketing activities were suspended. As part of the Amendment with Takeda, the profit equalization revenue for the three months ended March 31, 2013 will be the final profit equalization payment under the Arrangement. Upon signing the Amendment with Takeda, the economics of the collaboration changed from a profit sharing arrangement to a milestone and royalty-based compensation structure to us, effective April 1, 2013.
	•	Milestone revenue. We account for milestones under ASU No. 2010-17, Milestone Method of Revenue Recognition. Under the milestone method, contingent consideration received from the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved, which we believe is more consistent with the substance of our performance under the collaboration. A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity’s performance or on the occurrence of a specific outcome resulting from the entity’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, and (iii) that would result in additional payments being due to the entity. A milestone is substantive if the consideration earned from the achievement of the milestone is consistent with our performance required to achieve the milestone or the increase in value to the collaboration resulting from our performance, relates solely to our past performance, and is reasonable relative to all of the other deliverables and payments within the collaboration. Although we are eligible to receive future milestones from Takeda, timing and amounts of future milestone payments, if any are highly uncertain due to the recall.
	Below is a summary of the components of our collaboration revenue for the three and nine months ended September 30, 2013, and 2012 (in thousands):
		Three months ended September 30, 2013						Nine months ended September 30, 2013
		2013			2012			2013		2012
	Profit equalization payment	$	—		$	10,377		$	5	$	13,048
	Milestone payments	—			2,250			—		60,250
	Revenue previously deferred related to API	—			441			—		441
	Net expense reimbursement after CAPM	—			535			1,364		5,823
	Total collaboration revenue	$	—		$	13,603		$	1,369	$	79,562
	License and Royalty Revenue
	Royalties are recognized as earned in accordance with contract terms, when third party results are reported and collectability is reasonably assured.  Royalties received under agreements that were acquired by us in the 2001 spin out from GlaxoSmithKline or Glaxo are recorded net of the 50% that we are required to remit to Glaxo.
	If Takeda decides to reintroduce OMONTYS, which is highly uncertain, we are eligible to receive potential milestones and royalties. The royalties are tiered in the range of 13% to 17% with respect to net sales in the U.S. and in the range of 13% to 24% depending on the level of net sales by Takeda worldwide outside of the U
Inventory	'
	Inventory
	We value our inventories at the lower of cost or net realizable value which is contractually determined in our collaboration with Takeda to be our cost plus a markup.  We determine the cost of inventory using the specific identification method.  We record active pharmaceutical ingredient, or API, as inventory when the title transfers to us from the contract manufacturing organization, or CMO, until the point of acceptance by Takeda. We initiate orders for API with our CMOs based on forecasts from Takeda. To date, all orders have generally commenced once there was a contractual commitment for the API from Takeda.
	We analyze our inventory levels quarterly and write down inventory that has become obsolete or has a cost basis in excess of its expected net realizable value, as well as any inventory quantities in excess of expected requirements.  Any expired inventory is disposed of and the related costs are recognized as expense. The voluntary recall of OMONTYS in February 2013 impacted the recoverability of our inventories based on assumptions about expected demand and net realizable value. In the December 31, 2012 balance sheet, given the significant uncertainty of demand following the recall, we had written down our API inventory and prepayments made to our CMOs to the net realizable value of zero. We also established an accrual for estimated losses on firm inventory purchase commitments by applying the same lower of cost or market approach that is used to value inventory. As of March 31, 2013 this accrued commitment was $32.9 million. However, in the second quarter, we were able to settle these obligations for $11.0 million resulting in a favorable adjustment to our operating results of $21.9 million in the quarter ended June 30, 2013. As of September 30, 2013, there was no remaining accrued balance.
	We expense costs relating to the production of API as research and development or R&D expense in the period incurred until we receive FDA approval for a new product or product configuration and began to capitalize the subsequent inventory costs relating to that product or product configuration. Prior to approval of OMONTYS for commercial sale in March 2012 by the FDA, we had expensed all costs associated with the production of API as R&D expense. Subsequent to receiving FDA approval of OMONTYS, we commenced capitalization of third party costs which are incurred to manufacture the API used in the production of OMONTYS.
Property and Equipment	'
	Property and Equipment
	Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are calculated using the straight-line method over the estimated useful lives of the assets, generally three to five years. Assets under capital lease and leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the related lease. Maintenance and repairs are charged to operations as incurred.
Valuation of Long-Lived Assets	'
	Valuation of Long-Lived Assets, Prepaids and Other Assets
	We assess the impairment of long-lived assets when events or changes in circumstances indicate that the carrying value of the assets or the asset grouping may not be recoverable. Factors that we consider in deciding when to perform an impairment review include significant negative industry or economic trends, and significant changes or planned changes in our use of the assets. We measure the recoverability of assets that will continue to be used in our operations by comparing the carrying value of the asset grouping to our estimate of the related total future undiscounted net cash flows. If an asset grouping's carrying value is not recoverable through the related undiscounted cash flows, the asset grouping is considered to be impaired. The impairment is measured by comparing the difference between the asset grouping's carrying value and its fair value. Fair value is the price that would be received from selling an asset in an orderly transaction between market participants at the measurement date. Long-lived assets such as intangible assets and property, plant and equipment are considered non-financial assets, and are recorded at fair value only when an impairment charge is recognized. The recall of OMONTYS was considered to be an impairment indicator for certain assets. We evaluated the recoverability of our assets and determined that certain assets were impaired. We recorded impairment charges for the nine months ended September 30, 2013 of $4.4 million. These charges are reflected in the statement of comprehensive income (loss) under the caption "Impairment (gain on disposal) of prepaid expenses, fixed assets, and intangible assets."
Net Income (Loss) Per Common Share	'
	Net Loss Per Common Share
	Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for potential common shares.
	Diluted net loss per share is computed similarly to basic net loss per share, except that the denominator is increased to include all dilutive potential common shares using the treasury stock method.  For purposes of this calculation, options to purchase common stock, common stock issuable pursuant to the 2006 Employee Stock Purchase Plan, restricted stock units, or RSUs, and warrants are considered to be potential common shares and are only included in the calculation of diluted (loss) income per share when their effect is dilutive.
	The following shares were excluded in the computation of diluted net loss per common share for the periods presented because including them would have an anti-dilutive effect (in thousands):
		Three months ended September 30, 2013					Nine months ended September 30, 2013
		2013		2012			2013		2012
	Options to purchase common stock	1,893		5,311			1,893		5,311
	Common stock issuable pursuant to the 2006 Employee Stock Purchase Plan	—		125			—		125
	Restricted stock units	—		317			—		317
	Warrant to purchase common stock	424		504			424		504
Stock-Based Compensation	'
	Stock-Based Compensation
	We account for equity instruments issued to employees and directors under the authoritative guidance for share-based payments.
	The equity instruments we most typically grant are stock options and RSUs. Stock options are valued using the Black-Scholes valuation model while the fair value of RSUs is equivalent to the market value of the equivalent number of shares of common stock on the date of grant. The measurement of stock-based compensation is subject to periodic adjustments as the underlying equity instruments vest or do not vest as a result of employee terminations prior to vest.
	We have issued stock options to non-employees. We account for equity instruments issued to non-employees in accordance with the authoritative guidance for equity-based payments to non-employees, using a fair value approach.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Summary of the components of collaboration revenue	'
	Below is a summary of the components of our collaboration revenue for the three and nine months ended September 30, 2013, and 2012 (in thousands):
		Three months ended September 30, 2013						Nine months ended September 30, 2013
		2013			2012			2013		2012
	Profit equalization payment	$	—		$	10,377		$	5	$	13,048
	Milestone payments	—			2,250			—		60,250
	Revenue previously deferred related to API	—			441			—		441
	Net expense reimbursement after CAPM	—			535			1,364		5,823
	Total collaboration revenue	$	—		$	13,603		$	1,369	$	79,562
Schedule of antidilutive shares excluded from the computation of diluted net loss per common share	'
	The following shares were excluded in the computation of diluted net loss per common share for the periods presented because including them would have an anti-dilutive effect (in thousands):
		Three months ended September 30, 2013					Nine months ended September 30, 2013
		2013		2012			2013		2012
	Options to purchase common stock	1,893		5,311			1,893		5,311
	Common stock issuable pursuant to the 2006 Employee Stock Purchase Plan	—		125			—		125
	Restricted stock units	—		317			—		317
	Warrant to purchase common stock	424		504			424		504

Balance_Sheet_Components_Table

Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Property and equipment	'
	Property and equipment consist of the following (in thousands):
		September 30,		December 31,
		2013		2012
	Leasehold improvements	$	—	$	2,501
	Equipment	—		9,794
	Software	—		3,064
	Construction in progress	—		9
		—		15,368
	Less: Accumulated depreciation and amortization	—		(12,387		)
		$	—	$	2,981
Accrued liabilities	'
	Accrued liabilities consist of the following (in thousands):
		September 30,		December 31,
		2013		2012
	Accrued potential losses related to firm purchase commitments (1)	$	—	$	34,599
	Restructuring accrual (2)	587		—
	Compensation-related expenses	—		12,837
	SG&A related costs	241		3,633
	R&D related costs	—		830
	Other	—		623
		$	828	$	52,522

Investments_Tables

Investments (Tables)	9 Months Ended
	Sep. 30, 2013
Available-for-sale Securities [Abstract]	'
Summary of available-for-sale marketable securities	'
	We held no investments as of September 30, 2013. A summary of our investments outstanding as of December 31, 2012 is as follows (in thousands):
		As of December 31, 2012
		Cost		Gross		Gross			Fair Value
				Unrealized		Unrealized
				Gains		Losses
	Short-term investments:
	Certificates of deposit	$	1,300	$	—	$	—		$	1,300
	Corporate debt securities	8,416		1		—			8,417
	Total short-term investments	$	9,716	$	1	$	—		$	9,717
	Long-term investments:
	Corporate debt securities	$	2,326	$	—	$	(3	)	$	2,323
	Total long-term investments	$	2,326	$	—	$	(3	)	$	2,323

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Schedule of investments measured at fair value on a recurring basis classified by the fair value measurements and disclosures valuation hierarchy	'
	The following table presents as of December 31, 2012 our investments measured at fair value on a recurring basis classified by the fair value measurements and disclosures valuation hierarchy (in thousands):
		As of December 31, 2012
				Fair Value Measurements Using
		Total		Level 1		Level 2		Level 3
	Money market funds	$	45,999	$	45,999	$	—	$	—
	Short-term investments:
	Certificates of deposit	$	1,300	$	—	$	1,300	$	—
	Corporate debt securities	8,417		—		8,417		—
	Total short-term investments	$	9,717	$	—	$	9,717	$	—
	Long term investments:
	Corporate debt securities	$	2,323	$	—	$	2,323	$	—
	Total long-term investments	$	2,323	$	—	$	2,323	$	—

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of stock-based compensation recorded in the statements of operations	'
	Stock-based compensation was recorded in the statements of operations as follows (in thousands):
		Three Months Ended September 30,						Nine Months Ended
								September 30,
		2013			2012			2013			2012
	Research and development	$	—		$	1,086		$	825		$	3,240
	Selling, general and administrative	499			1,719			2,747			4,747
	Total	$	499		$	2,805		$	3,572		$	7,987
Schedule of stock options and restricted stock units to employees and directors	'
	We granted the following stock options, RSUs and performance RSUs, or PRSUs to employees as follows:
		Nine Months Ended September 30,
		2013
		Number of		Weighted-
		Shares		Average Grant
				Date Fair Value
				Per Share
	Stock options	888,778		$	15.79
	Restricted stock units	331,195		$	19.42
	Performance restricted stock units	62,000		$	19.43
	The following tables summarize information about stock option and RSU activity for the nine months ended September 30, 2013:
		Number of		Weighted-			Weighted-		Aggregate
		Shares		Average Exercise Price			Average		Intrinsic Value
				(Per Share)(1)			Remaining		(in thousands)(2)
							Contractual
							Term
							(in years)
	Stock Options:
	Balances at December 31, 2012	4,857,536		$	13.49
	Granted	888,778		18.83
	Exercised	(30,918	)	8.77
	Forfeited	(2,889,025	)	13.35
	Cancelled	(933,724	)	13.08
	Balances at September 30, 2013	1,892,647		$	16.49		3.71		$	—
	Options exercisable at September 30, 2013	1,549,755		$	17.5		2.76		$	—
		Number of		Weighted-			Weighted-		Aggregate
		Shares		Average Grant Date Fair Value			Average		Intrinsic Value
				(Per Share)(1)			Remaining		(in thousands)(2)
							Contractual
							Term
							(in years)
	Restricted Stock Units:
	Balances at December 31, 2012	296,723		$	7.54
	Granted (time-based)	393,195		19.42
	Vested	(89,502	)	7.58
	Forfeited	(600,416	)	15.19
	Balances at September 30, 2013	—		$	—		0		$	—
	_______________________________________________________________________________
	-1	The weighted average price per share is determined using exercise price per share for stock options and fair value per share on grant date for restricted stock units.
	-2	The aggregate intrinsic value is calculated as:
	•	For options: the difference between the exercise price of the option and the fair value of our common stock for in-the-money options at September 30, 2013.
	•	For restricted stock units: the difference between the grant date fair value of the unit and the fair value of our common stock for in-the-money units at September 30, 2013.

Restructuring_Charge_Tables

Restructuring Charge (Tables)	9 Months Ended
	Sep. 30, 2013
Restructuring and Related Activities [Abstract]	'
Summarizes the accrual balance and utilization by type for the restructuring	'
	The following table summarizes the accrual balance and utilization by type for the restructuring (in thousands):
		Facilities			Employee			Total
		Related			Related
	Balance at December 31, 2012	$	—		$	—		$	—
	Restructuring charges accrued	2,500			13,841			16,341
	Adjustments	—			214			214
	Cash payments	(2,500		)	(13,451		)	(15,951		)
	Accretion	(17		)	—			(17		)
	Balance at September 30, 2013	$	(17	)	$	604		$	587

The_Company_Details

The Company (Details) (USD $)

3 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Sep. 30, 2013

employees

employees

Takeda Pharmaceutical Company Limited [Member]

Takeda Pharmaceutical Company Limited [Member]

Takeda Pharmaceutical Company Limited [Member]

Takeda Pharmaceutical Company Limited [Member]

Takeda Pharmaceutical Company Limited [Member]

Takeda Pharmaceutical Company Limited [Member]

Takeda Pharmaceutical Company Limited [Member]

Takeda Pharmaceutical Company Limited [Member]

Takeda Pharmaceutical Company Limited [Member]

Takeda Pharmaceutical Company Limited [Member]

2013 Restructuring Plan [Member]

2013 Restructuring Plan [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

United States of America [Member]

United States of America [Member]

Foreign [Member]

Foreign [Member]

Aggregate Net Sales Reached [Member]

First Commercial Sale After Reintroduction of O.M.O.N.T.Y.S [Member]

U.S Sales-based Milestone One [Member]

U.S Sales-based Milestone Two [Member]

Milestone Payment Based On Sales Foreign Sales Based Milestone [Member]

employees

Takeda Pharmaceutical Company Limited [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

United States of America [Member]

Restructuring Cost and Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Entity Number of Employees

4

'

4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accumulated deficit

($556,706,000)

'

($556,706,000)

'

($543,713,000)

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of positions planned to be reduced as per the restructuring plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

305

'

'

Restructuring charge

138,000

0

15,478,000

0

'

'

'

'

'

'

'

'

'

'

'

'

16,341,000

'

Potential commercial milestone payments

'

'

'

'

'

'

'

'

'

'

180,000,000

10,000,000

10,000,000

10,000,000

150,000,000

'

'

'

Potential development milestone payments

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Net sales royalties, percentage tiered

'

'

'

'

'

'

13.00%

17.00%

13.00%

24.00%

'

'

'

'

'

'

'

'

Advance from Takeda

$8,189,000

'

$8,189,000

'

$27,715,000

'

'

'

'

'

'

'

'

'

'

'

'

$8,189,000

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Concentration of Risk) (Details)	9 Months Ended
	Sep. 30, 2013
Concentration Risk [Line Items]	'
Concentration Risk, Product	'1

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Revenue Recognition) (Details) (USD $)

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Apr. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Takeda Pharmaceutical Company Limited [Member]

Takeda Pharmaceutical Company Limited [Member]

Takeda Pharmaceutical Company Limited [Member]

Takeda Pharmaceutical Company Limited [Member]

Takeda Pharmaceutical Company Limited [Member]

Affymax [Member]

Glaxo Smith Kline [Member]

United States of America [Member]

United States of America [Member]

Foreign [Member]

Foreign [Member]

Arrangement - Product [Member]

Arrangement - Product [Member]

Arrangement - Product [Member]

Arrangement - Product [Member]

Arrangement - Product [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Takeda Pharmaceutical Company Limited [Member]

Takeda Pharmaceutical Company Limited [Member]

Takeda Pharmaceutical Company Limited [Member]

Takeda Pharmaceutical Company Limited [Member]

Collaboration Revenue

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assets Held-for-sale, Property, Plant and Equipment

$0

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

Reimbursement Revenue

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

Components of collaboration revenue

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Profit equalization payment

'

'

'

'

'

0

10,377,000

5,000

13,048,000

'

'

'

'

'

'

Milestone payments

'

'

'

'

'

0

2,250,000

0

60,250,000

'

'

'

'

'

'

Revenue Recognition Revenue Previously Deferred Related to Active Pharmaceutical Ingredient

'

'

'

'

'

0

441,000

0

441,000

'

'

'

'

'

'

Net expense reimbursement after CAPM

'

'

'

'

'

0

535,000

1,364,000

5,823,000

'

'

'

'

'

'

Total collaboration revenue

$0

$13,603,000

$1,364,000

$79,562,000

'

$0

$13,603,000

$1,369,000

$79,562,000

'

'

'

'

'

'

License and Royalty Revenue

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of royalties received to royalties required to be remitted to Glaxo

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

Profit share

'

'

'

'

'

'

'

50.00%

'

50.00%

'

'

'

'

'

Expense reimbursement revenue

'

'

'

'

'

'

'

70.00%

'

30.00%

'

'

'

'

'

Commercialization expense

'

'

'

'

'

'

'

50.00%

'

50.00%

'

'

'

'

'

Net sales royalties, percentage tiered

'

'

'

'

'

'

'

'

'

'

'

13.00%

17.00%

13.00%

24.00%

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Inventory) (Details) (USD $)	3 Months Ended
	Sep. 30, 2013		Mar. 31, 2013	Dec. 31, 2012
Purchase Commitment, Excluding Long-term Commitment [Line Items]	'		'	'
Purchase Commitment, Payment	$11,000,000		$1,700,000	'
Purchase Commitment Reserve, Accrual Adjustment	21,900,000		'	'
Accrued potential losses related to firm purchase commitments	0	[1]	32,900,000	34,599,000	[1]
Commercial API Supply Agreement [Member]	'		'	'
Purchase Commitment, Excluding Long-term Commitment [Line Items]	'		'	'
Inventory, net realizable value	0		'	'
Accrued potential losses related to firm purchase commitments	'		'	$10,400,000
[1]	See Note 3 of Notes to Condensed Financial Statements.

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Property and Equipment) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Impairment (gain on disposal) of prepaid expenses, fixed assets and intangible assets	($166)	$0	$4,414	$0	'
Assets Held-for-sale, Property, Plant and Equipment	0	'	0	'	'
Property and equipment, net	0	'	0	'	2,981
Minimum [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Estimated useful lives of assets	'	'	'3 years	'	'
Maximum [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Estimated useful lives of assets	'	'	'5 years	'	'
Assets Sold [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, net	$500	'	$500	'	'

Summary_of_Significant_Account7

Summary of Significant Accounting Policies (Net Loss Per Common Share) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Net (loss) income	($1,692)	($24,638)	($12,993)	($25,141)
Options to purchase common stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities	1,893	5,311	1,893	5,311
Common stock issuable pursuant to the 2006 Employee Stock Purchase Plan [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities	0	125	0	125
Restricted Stock Units (RSUs) [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities	0	317	0	317
Warrant to purchase common stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities	424	504	424	504

Development_and_Commercializat1

Development and Commercialization Agreements with Takeda (Prior to April 2013 Amendment) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Development and Commercialization agreements with Takeda	'	'	'	'	'
Collaboration revenue recognized	$0	$13,603	$1,364	$79,562	'
Receivable from Takeda	0	'	0	'	18,365
Affymax [Member] | Collaborative Arrangement Product February 2012 [Member]	'	'	'	'	'
Development and Commercialization agreements with Takeda	'	'	'	'	'
Profit equalization percentage as outlined in collaboration agreement	'	'	50.00%	'	'
Affymax [Member] | Product Development and Commercialization [Member]	'	'	'	'	'
Development and Commercialization agreements with Takeda	'	'	'	'	'
Expense reimbursement revenue	'	'	30.00%	'	'
Profit equalization percentage as outlined in collaboration agreement	'	'	50.00%	'	'
Takeda Pharmaceutical Company Limited [Member] | Collaborative Arrangement Product February 2012 [Member]	'	'	'	'	'
Development and Commercialization agreements with Takeda	'	'	'	'	'
Profit equalization percentage as outlined in collaboration agreement	'	'	50.00%	'	'
Takeda Pharmaceutical Company Limited [Member] | Product Development and Commercialization [Member]	'	'	'	'	'
Development and Commercialization agreements with Takeda	'	'	'	'	'
Collaborative Arrangement, Number of Agreements	'	'	2	'	'
Expense reimbursement revenue	'	'	70.00%	'	'
Profit equalization percentage as outlined in collaboration agreement	'	'	50.00%	'	'
Collaboration revenue recognized	0	13,603	1,369	79,562	'
Takeda Pharmaceutical Company Limited [Member] | Commercial API Supply Agreement [Member]	'	'	'	'	'
Development and Commercialization agreements with Takeda	'	'	'	'	'
Potential estimated obligations	'	'	50.00%	'	'
Takeda Pharmaceutical Company Limited [Member] | Cost sharing agreements [Member] | Product Development and Commercialization [Member]	'	'	'	'	'
Development and Commercialization agreements with Takeda	'	'	'	'	'
Cost sharing percentage of third party development expenses	'	'	70.00%	'	'
United States of America [Member] | Takeda Pharmaceutical Company Limited [Member] | Launch Allowance - Cost sharing agreements [Member] | Product Development and Commercialization [Member]	'	'	'	'	'
Development and Commercialization agreements with Takeda	'	'	'	'	'
Percentage of third-party commercialization expenses to be borne	'	'	50.00%	'	'
Takeda Pharmaceutical Company Limited [Member]	'	'	'	'	'
Development and Commercialization agreements with Takeda	'	'	'	'	'
Receivable from Takeda	$0	'	$0	'	$18,400

Development_and_Commercializat2

Development and Commercialization Agreements with Takeda (Outside the U.S.) (Details) (USD $)	Sep. 30, 2013
Development and Commercialization Agreements [Abstract]	'
Potential sales-based milestone	$0
Takeda Pharmaceutical Company Limited [Member] | Milestone payment based on regulatory, commercial or clinical development [Member] | Product Development and Commercialization - February 2006 Agreement [Member] | Japan [Member]	'
Development and Commercialization agreements with Takeda	'
Potential Development Milestones	33,000,000
Potential milestone payments not pursued	$5,000,000

Development_and_Commercializat3

Development and Commercialization Agreements with Takeda (Launch Allowance) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
			Takeda Pharmaceutical Company Limited [Member]	Takeda Pharmaceutical Company Limited [Member]	Takeda Pharmaceutical Company Limited [Member]	Takeda Pharmaceutical Company Limited [Member]	United States of America [Member]	United States of America [Member]	United States of America [Member]
			Product Development and Commercialization [Member]	Product Development and Commercialization [Member]	Product Development and Commercialization [Member]	Product Development and Commercialization [Member]	Takeda Pharmaceutical Company Limited [Member]	Takeda Pharmaceutical Company Limited [Member]	Takeda Pharmaceutical Company Limited [Member]
							Product Development and Commercialization [Member]	Product Development and Commercialization - June 2006 Agreement [Member]	Product Development and Commercialization - June 2006 Agreement [Member]
							Launch Allowance - Cost sharing agreements [Member]		Launch Allowance - Cost sharing agreements [Member]
Development and Commercialization agreements with Takeda	'	'	'	'	'	'	'	'	'
Percentage of third-party commercialization expenses to be borne	'	'	'	'	'	'	50.00%	'	'
Payments received from collaborative agreement	'	'	'	'	'	'	'	'	$20,000,000
Percentage of net sales deducted from the profit share	'	'	'	'	'	'	'	'	8.00%
Amount of threshold limit of deduction from net sales from the profit share	'	'	'	'	'	'	'	'	11,000,000
Advance from Takeda	8,189,000	27,715,000	'	'	'	'	'	8,189,000	10,000,000
Fixed interest amount	'	'	'	'	'	'	'	'	1,000,000
Profit equalization payment	'	'	$0	$10,377,000	$5,000	$13,048,000	'	'	'

Development_and_Commercializat4

Development and Commercialization Agreements with Takeda (Milestones) (Details) (Takeda Pharmaceutical Company Limited [Member], USD $)

9 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2012

Mar. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Milestone payment upon FDA approval [Member]

Milestone payment upon FDA approval [Member]

Milestone payment upon acceptance of MAA filing for OMONTYS by EMA [Member]

Milestone payment based on regulatory, commercial or clinical development [Member]

Milestone payment based on regulatory, commercial or clinical development [Member]

Milestone payment resulting from progress on the commercial launch of OMONTYS [Member]

Aggregate Net Sales Reached [Member]

First Commercial Sale After Reintroduction of O.M.O.N.T.Y.S [Member]

U.S Sales-based Milestone One [Member]

U.S Sales-based Milestone Two [Member]

Milestone Payment Based On Sales Foreign Sales Based Milestone [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Sale Based Milestone $10 million [Member]

Sale Based Milestone $20 million [Member]

Sale Based Milestone $30 million [Member]

Sale Based Milestone $40 million [Member]

Sale Based Milestone $50 million [Member]

Sales Based Milestone $.5 billion [Member]

Sales Based Milestone $1 billion [Member]

Sales Based Milestone $1.5 billion [Member]

Sales Based Milestone $2 billion [Member]

Sales Based Milestone $3 billion [Member]

United States of America [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

United States of America [Member]

United States of America [Member]

Settlement and license agreement with Janssen [Member]

United States of America [Member]

Foreign [Member]

United States of America [Member]

Foreign [Member]

Aggregate Net Sales Reached [Member]

Aggregate Net Sales Reached [Member]

Aggregate Net Sales Reached [Member]

Aggregate Net Sales Reached [Member]

Aggregate Net Sales Reached [Member]

Aggregate Net Sales Reached [Member]

Aggregate Net Sales Reached [Member]

Aggregate Net Sales Reached [Member]

Aggregate Net Sales Reached [Member]

Aggregate Net Sales Reached [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

Settlement and license agreement with Janssen [Member]

Settlement and license agreement with Janssen [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

Product Development and Commercialization - June 2006 Agreement [Member]

Development and Commercialization agreements with Takeda

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Milestones recognized as revenue

'

'

$50,000,000

$5,000,000

$3,000,000

$3,000,000

$2,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate amount receivable if clinical development and regulatory milestones are successfully achieved

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000,000

20,000,000

30,000,000

40,000,000

50,000,000

500,000,000

1,000,000,000

1,500,000,000

2,000,000,000

3,000,000,000

Potential commercial milestone payments

'

'

'

'

'

'

'

180,000,000

10,000,000

10,000,000

10,000,000

150,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Potential development milestone payments

$5,000,000

$5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net sales royalties, percentage tiered

'

'

'

'

'

'

'

'

'

'

'

'

13.00%

13.00%

17.00%

24.00%

'

'

'

'

'

'

'

'

'

'

Development_and_Commercializat5

Development and Commercialization Agreements with Takeda (API Supply Agreement) (Details) (USD $)	Dec. 31, 2012	Sep. 30, 2013
In Millions, unless otherwise specified		Takeda Pharmaceutical Company Limited [Member]
		Commercial API Supply Agreement [Member]
		Arrangement - Co-promotion [Member]
Development and Commercialization agreements with Takeda	'	'
Additional reimbursement percentage	'	20.00%
Advances on inventory purchases	$19.80	'

Development_and_Commercializat6

Development and Commercialization Agreements with Takeda (Impairment of Inventory and Firm Purchase Commitments) (Details) (USD $)	3 Months Ended				9 Months Ended			12 Months Ended
	Sep. 30, 2013		Mar. 31, 2013	Sep. 30, 2012	Sep. 30, 2013		Sep. 30, 2012	Dec. 31, 2012
Development and Commercialization agreements with Takeda	'		'	'	'		'	'
Purchase Commitment, Payment	$11,000,000		$1,700,000	'	'		'	'
Purchase Commitment Reserve, Accrual Adjustment	21,900,000		'	'	'		'	'
Accrued potential losses related to firm purchase commitments	0	[1]	32,900,000	'	0	[1]	'	34,599,000	[1]
Collaboration Cost Reimbursement	'		'	'	-43,451,000		0	'
Asset Impairment Charges, Inventory and Firm Purchase Commitments	'		'	'	'		'	45,000,000
Commercial API Supply Agreement [Member]	'		'	'	'		'	'
Development and Commercialization agreements with Takeda	'		'	'	'		'	'
Accrued potential losses related to firm purchase commitments	'		'	'	'		'	10,400,000
Inventory, net realizable value	0		'	'	0		'	'
Inventory write-down	'		'	'	$10,400,000		'	'
[1]	See Note 3 of Notes to Condensed Financial Statements.

Development_and_Commercializat7

Development and Commercialization Agreements with Takeda (Cost of Recall) (Details) (USD $)	3 Months Ended	9 Months Ended	3 Months Ended			12 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2013	Sep. 30, 2013	Mar. 31, 2013	Mar. 31, 2013	Mar. 31, 2013	Dec. 31, 2012
	Commercial API Supply Agreement [Member]	Commercial API Supply Agreement [Member]	Minimum [Member]	Baxter Prefilled Syringes Agreement [Member]	Commercial API Supply Agreement [Member]	Commercial API Supply Agreement [Member]
			Commercial API Supply Agreement [Member]	Takeda Pharmaceutical Company Limited [Member]	Takeda Pharmaceutical Company Limited [Member]	Affymax [Member]
Development and Commercialization agreements with Takeda	'	'	'	'	'	'
Inventory recall expense	'	'	$1.10	'	'	'
Profit equalization losses	0.6	'	'	'	'	'
Inventory write-down	'	10.4	'	'	31.8	15.9
Purchase commitment	'	'	'	9.3	'	'
Accrued liabilities	'	'	'	0.7	'	'
Impairment charge on held for use equipment	'	'	'	'	$6.20	'

Development_and_Commercializat8

Development and Commercialization Agreements with Takeda (November 2011 Amendment) (Details) (USD $)	Sep. 30, 2013	Nov. 30, 2011	Mar. 31, 2012	Dec. 31, 2012	Nov. 30, 2011	Nov. 30, 2011
In Thousands, unless otherwise specified		Milestone payments resulting from settlement and license agreement with Janssen [Member]	United States of America [Member]	United States of America [Member]	United States of America [Member]	European Union [Member]
		Takeda Pharmaceutical Company Limited [Member]	Milestone payment based on regulatory, commercial or clinical development [Member]	Milestone payment based on regulatory, commercial or clinical development [Member]	Milestone payment based on regulatory, commercial or clinical development [Member]	Milestone payment based on regulatory, commercial or clinical development [Member]
		Settlement and license agreement with Janssen [Member]	Takeda Pharmaceutical Company Limited [Member]	Takeda Pharmaceutical Company Limited [Member]	Takeda Pharmaceutical Company Limited [Member]	Takeda Pharmaceutical Company Limited [Member]
			Settlement and license agreement with Janssen [Member]	Settlement and license agreement with Janssen [Member]	Settlement and license agreement with Janssen [Member]	Settlement and license agreement with Janssen [Member]
Development and Commercialization agreements with Takeda	'	'	'	'	'	'
Potential sales-based milestone	$0	$6,500	'	'	$5,300	$1,300
Milestones recognized as revenue	'	'	$3,000	$3,000	'	'

Contractual_Arrangements_Detai

Contractual Arrangements (Details) (USD $)

3 Months Ended

9 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Sep. 30, 2013

Apr. 30, 2012

Mar. 31, 2012

Jun. 30, 2012

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Purchase Comment PEG [Member]

Purchase Commitment API [Member]

Settlement and license agreement with Janssen [Member]

Settlement and license agreement with Janssen [Member]

Settlement and license agreement with Janssen [Member]

Settlement and license agreement with Janssen [Member]

Settlement and license agreement with Janssen [Member]

Settlement and license agreement with Janssen [Member]

Settlement and license agreement with Janssen [Member]

Settlement and license agreement with Janssen [Member]

Fixed payments [Member]

Fixed payments [Member]

Fixed payments [Member]

Milestone payment upon FDA regulatory approval of OMONTYS [Member]

Milestone payment upon FDA regulatory approval of OMONTYS in the first major European country [Member]

numberofagreements

Development and Commercialization agreements with Takeda

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Potential sales-based milestone

$0

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

Accrued Losses Purchase Commitments

0

[1]

32,900,000

'

0

[1]

'

34,599,000

[1]

5,800,000

28,800,000

'

'

'

'

'

'

'

'

Purchase Commitment, Payment

11,000,000

1,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase Commitment Reserve, Accrual Adjustment

21,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of fixed payments to be made under the agreement

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

Fixed or milestone payments

'

'

'

'

'

'

'

'

'

'

'

2,000,000

6,000,000

'

2,500,000

'

Research and development

-166,000

'

11,416,000

11,805,000

40,486,000

'

'

'

'

'

'

'

'

8,000,000

'

'

Amount of fixed payments to be made under the agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500,000

Amount capitalized relating to first milestone payment

'

'

'

'

'

'

'

'

'

2,500,000

2,500,000

'

'

'

'

'

Impairment (gain on disposal) of prepaid expenses, fixed assets and intangible assets

($166,000)

'

$0

$4,414,000

$0

'

'

'

$1,900,000

'

'

'

'

'

'

'

[1]

See Note 3 of Notes to Condensed Financial Statements.

Balance_Sheet_Components_Prope

Balance Sheet Components (Property and Equipment, Net) (Details) (USD $)	3 Months Ended	6 Months Ended	9 Months Ended
	Sep. 30, 2013	Jun. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	$0	'	$0	'	$15,368,000
Less: Accumulated depreciation and amortization	0	'	0	'	-12,387,000
Property and equipment, net	0	'	0	'	2,981,000
Depreciation and amortization expense	'	1,500,000	574,000	1,450,000	'
Impairment charges	'	'	1,900,000	'	'
Proceeds from sale of property and equipment	1,100,000	'	1,225,000	25,000	'
Gain (Loss) on Sale of Property Plant Equipment	600,000	'	704,000	-30,000	'
Assets Sold [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, net	500,000	'	500,000	'	'
Leasehold improvements [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	0	'	0	'	2,501,000
Equipment [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	0	'	0	'	9,794,000
Software [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	0	'	0	'	3,064,000
Construction in progress [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	$0	'	$0	'	$9,000

Balance_Sheet_Components_Accru

Balance Sheet Components (Accrued Liabilities) (Details) (USD $)	Sep. 30, 2013		Mar. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accrued Liabilities [Abstract]	'		'	'
Accrued potential losses related to firm purchase commitments	$0	[1]	$32,900	$34,599	[1]
Restructuring accrual	587	[2]	'	0	[2]
Compensation-related expenses	0		'	12,837
SG&A related costs	241		'	3,633
R&D related costs	0		'	830
Other	0		'	623
Accrued liabilities	$828		'	$52,522
[1]	See Note 3 of Notes to Condensed Financial Statements.
[2]	See Note 11 of Notes to Condensed Financial Statements.

Investments_Details

Investments (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Available-for-sale marketable securities	'	'
Fair Value	$0	$9,717
Short-term investments [Member]	'	'
Available-for-sale marketable securities	'	'
Cost	'	9,716
Gross Unrealized Gains	'	1
Gross Unrealized Losses	'	0
Fair Value	'	9,717
Short-term investments [Member] | Certificates of deposit [Member]	'	'
Available-for-sale marketable securities	'	'
Cost	'	1,300
Gross Unrealized Gains	'	0
Gross Unrealized Losses	'	0
Fair Value	'	1,300
Short-term investments [Member] | Corporate debt securities [Member]	'	'
Available-for-sale marketable securities	'	'
Cost	'	8,416
Gross Unrealized Gains	'	1
Gross Unrealized Losses	'	0
Fair Value	'	8,417
Long-term investments [Member]	'	'
Available-for-sale marketable securities	'	'
Cost	'	2,326
Gross Unrealized Gains	'	0
Gross Unrealized Losses	'	-3
Fair Value	'	2,323
Long-term investments [Member] | Corporate debt securities [Member]	'	'
Available-for-sale marketable securities	'	'
Cost	'	2,326
Gross Unrealized Gains	'	0
Gross Unrealized Losses	'	-3
Fair Value	'	$2,323

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Short-term investments:	'	'
Short-term investments	$0	$9,717,000
Long-term Investments:	'	'
Long-term investments	0	2,323,000
Property, Plant and Equipment, Net	0	2,981,000
Liabilities, Fair Value Disclosure, Recurring	0	'
Assets, Fair Value Disclosure, Recurring	0	'
Short-term investments [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	9,717,000
Short-term investments [Member] | Certificates of deposit [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	1,300,000
Short-term investments [Member] | Corporate debt securities [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	8,417,000
Long-term investments [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	2,323,000
Long-term investments [Member] | Corporate debt securities [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	2,323,000
Recurring [Member] | Total [Member]	'	'
Fair value measurements	'	'
Money market funds	'	45,999,000
Recurring [Member] | Total [Member] | Short-term investments [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	9,717,000
Recurring [Member] | Total [Member] | Short-term investments [Member] | Certificates of deposit [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	1,300,000
Recurring [Member] | Total [Member] | Short-term investments [Member] | Corporate debt securities [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	8,417,000
Recurring [Member] | Total [Member] | Long-term investments [Member]	'	'
Long-term Investments:	'	'
Long-term investments	'	2,323,000
Recurring [Member] | Total [Member] | Long-term investments [Member] | Corporate debt securities [Member]	'	'
Long-term Investments:	'	'
Long-term investments	'	2,323,000
Recurring [Member] | Level 1 [Member]	'	'
Fair value measurements	'	'
Money market funds	'	45,999,000
Recurring [Member] | Level 1 [Member] | Short-term investments [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	0
Recurring [Member] | Level 1 [Member] | Short-term investments [Member] | Certificates of deposit [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	0
Recurring [Member] | Level 1 [Member] | Short-term investments [Member] | Corporate debt securities [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	0
Recurring [Member] | Level 1 [Member] | Long-term investments [Member]	'	'
Long-term Investments:	'	'
Long-term investments	'	0
Recurring [Member] | Level 1 [Member] | Long-term investments [Member] | Corporate debt securities [Member]	'	'
Long-term Investments:	'	'
Long-term investments	'	0
Recurring [Member] | Level 2 [Member]	'	'
Fair value measurements	'	'
Money market funds	'	0
Recurring [Member] | Level 2 [Member] | Short-term investments [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	9,717,000
Recurring [Member] | Level 2 [Member] | Short-term investments [Member] | Certificates of deposit [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	1,300,000
Recurring [Member] | Level 2 [Member] | Short-term investments [Member] | Corporate debt securities [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	8,417,000
Recurring [Member] | Level 2 [Member] | Long-term investments [Member]	'	'
Long-term Investments:	'	'
Long-term investments	'	2,323,000
Recurring [Member] | Level 2 [Member] | Long-term investments [Member] | Corporate debt securities [Member]	'	'
Long-term Investments:	'	'
Long-term investments	'	2,323,000
Recurring [Member] | Level 3 [Member]	'	'
Fair value measurements	'	'
Money market funds	'	0
Recurring [Member] | Level 3 [Member] | Short-term investments [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	0
Recurring [Member] | Level 3 [Member] | Short-term investments [Member] | Certificates of deposit [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	0
Recurring [Member] | Level 3 [Member] | Short-term investments [Member] | Corporate debt securities [Member]	'	'
Short-term investments:	'	'
Short-term investments	'	0
Recurring [Member] | Level 3 [Member] | Long-term investments [Member]	'	'
Long-term Investments:	'	'
Long-term investments	'	0
Recurring [Member] | Level 3 [Member] | Long-term investments [Member] | Corporate debt securities [Member]	'	'
Long-term Investments:	'	'
Long-term investments	'	$0

Loan_and_Security_Agreement_De

Loan and Security Agreement (Details) (USD $)	0 Months Ended
In Millions, unless otherwise specified	Apr. 03, 2013	Mar. 31, 2012
Loan and Security Agreement	'	'
Notes Payable to Bank	'	$10
Extinguishment of debt	$9.80	'

Commitments_and_Contingencies_

Commitments and Contingencies Commitments and Contingencies (Details) (Purported Stockholders [Member], Pending Litigation [Member], USD $)	Sep. 30, 2013	Mar. 29, 2013	Mar. 19, 2013	Mar. 06, 2013	Feb. 27, 2013
	Derivatives Lawsuit [Member]	Derivatives Lawsuit [Member]	Derivatives Lawsuit [Member]	Securities Class Action Complaint [Member]	Securities Class Action Complaint [Member]
		lawsuits	lawsuits	lawsuits	lawsuits
Loss Contingencies [Line Items]	'	'	'	'	'
Loss on firm purchase commitments	$0	'	'	'	'
Number of pending claims	'	1	1	1	1

StockBased_Compensation_Statem

Stock-Based Compensation (Statements of Operations) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	$499	$2,805	$3,572	$7,987
Research and Development Expense [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	0	1,086	825	3,240
Selling, General and Administrative Expenses [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	$499	$1,719	$2,747	$4,747

StockBased_Compensation_Grants

Stock-Based Compensation (Grants and Weighted Average Grant Date Fair Value) (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Stock Options [Member]	'
Stock-based compensation	'
Granted (shares)	888,778
Weighted- average grant date fair value per share	$15.79
Restricted Stock Units (RSUs) [Member]	'
Stock-based compensation	'
Granted (shares)	331,195
Weighted- average grant date fair value per share	$19.42
Performance Restricted Stock Units [Member]	'
Stock-based compensation	'
Granted (shares)	62,000
Weighted- average grant date fair value per share	$19.43

StockBased_Compensation_Stock_

Stock-Based Compensation (Stock Options) (Details) (Stock Options [Member], USD $)	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013
Stock Options [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'
Share-based payment award, beginning balance (shares)	4,857,536
Granted (shares)	888,778
Exercised (shares)	-30,918
Forfeited (shares)	-2,889,025
Cancelled (shares)	-933,724
Share-based payment award, ending balance (shares)	1,892,647
Options exercisable (shares)	1,549,755
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]	'
Share-based payment award, beginning balance (per share)	$13.49	[1]
Granted (per share)	$18.83	[1]
Exercised (per share)	$8.77	[1]
Forfeited (per share)	$13.35	[1]
Cancelled (per share)	$13.08	[1]
Share-based payment award, ending balance (per share)	$16.49	[1]
Options exercisable (per share)	$17.50	[1]
Share-based Compensation Arrangement by Share-based Payment, Award, Options, Weighted Average Remaining Contractual Terms [Roll Forward]	'
Share-based payment award, ending balance, weighted average remaining contractual term	'3 years 8 months 15 days
Options exercisable weighted average remaining contractual term	'2 years 9 months 5 days
Share-based Compensation Arrangement by Share-based Payment, Award, Options, Intrinsic Value [Roll Forward]	'
Options, intrinsic value	$0	[2]
Options exercisable, Intrinsic value	$0	[2]
[1]	The weighted average price per share is determined using exercise price per share for stock options and fair value per share on grant date for restricted stock units.
[2]	The aggregate intrinsic value is calculated as:•For options: the difference between the exercise price of the option and the fair value of our common stock for in-the-money options at September 30, 2013.•For restricted stock units: the difference between the grant date fair value of the unit and the fair value of our common stock for in-the-money units at September 30, 2013.

StockBased_Compensation_Restri

Stock-Based Compensation (Restricted Stock Unit Activity) (Details) (Restricted Stock Units (RSUs) [Member], USD $)	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013
Restricted Stock Units (RSUs) [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'
Share-based payment award, beginning balance (shares)	296,723
Granted (time-based) (shares)	393,195
Vested (shares)	-89,502
Forfeited (shares)	-600,416
Share-based payment award, ending balance (shares)	0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]	'
Share-based payment award, beginning balance (per share)	$7.54	[1]
Granted (time-based) (per share)	$19.42	[1]
Vested (per share)	$7.58	[1]
Forfeited (per share)	$15.19	[1]
Share-based payment award, ending balance (per share)	$0	[1]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Remaining Contractual Term [Roll Forward]	'
Share-based payment award, ending balance, weighted average remaining contractual term	'0 years 0 months 1 day
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value [Roll Forward]	'
Share-based payment award, ending balance, intrinsic value	$0	[2]
[1]	The weighted average price per share is determined using exercise price per share for stock options and fair value per share on grant date for restricted stock units.
[2]	The aggregate intrinsic value is calculated as:•For options: the difference between the exercise price of the option and the fair value of our common stock for in-the-money options at September 30, 2013.•For restricted stock units: the difference between the grant date fair value of the unit and the fair value of our common stock for in-the-money units at September 30, 2013.

Restructuring_Charge_Details

Restructuring Charge (Details) (USD $)	3 Months Ended		9 Months Ended		3 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Mar. 31, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
					2013 Restructuring Plan [Member]	2013 Restructuring Plan [Member]	2013 Restructuring Plan [Member]	2013 Restructuring Plan [Member]
					employees		Facility Closing [Member]	Employee Related [Member]
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Number of positions planned to be reduced as per the restructuring plan	'	'	'	'	305	'	'	'
Accrual balance and utilization by type for the restructuring	'	'	'	'	'	'	'	'
Balance at the beginning of the period	'	'	'	'	$0	$0	$0	$0
Restructuring charge accrued	138	0	15,478	0	'	16,341	2,500	13,841
Adjustments	'	'	'	'	'	214	0	214
Cash payments	'	'	'	'	'	-15,951	2,500	-13,451
Accretion	'	'	'	'	'	-17	-17	0
Balance at the end of the period	'	'	'	'	'	$587	($17)	$604

Provision_for_Income_Taxes_Det

Provision for Income Taxes (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Tax Disclosure [Abstract]	'	'	'	'
(Benefit) provision for income taxes	$0	$0	($2,158)	$1